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Targeted drug delivery using aptamers is a new generation therapeutics that holds a 
great promise for effective treatment of cancer. Oligonucleotide aptamers, single-
stranded DNA (ssDNA) or RNA with affinity akin to that of antibodies, can virtually 
be selected against any target. In this study, the use of aptamers in cancer therapy was 
investigated in four subprojects. Firstly, a sensitive and facile gold nanoparticle 
(AuNP) based assay [with a detection limit of 8 nM mucin 1 (MUC1) peptide] was 
developed for peptide-aptamer affinity analysis. Secondly, MUC1 targeting aptamer 
was modified with polyethylene glycol (PEG) to avoid macrophage uptake. Thirdly, 
MUC1 targeting aptamer was modified to form tridentate aptamer to increase 
specificity toward MUC1 overexpressing breast cancer cells as compared to 
macrophages. Doxorubicin (DOX) was then intercalated within the modified aptamers, 
and the drug-aptamer complexes used for targeted drug delivery to breast cancer cells. 
Through these modifications, around 6-fold increase in macrophage viability (as 
compared to when free DOX was used) was achieved. Finally, various newly reported 
affinity ligands were assessed for their potential uses in bladder cancer drug delivery. 
Overall, this thesis provides insights into developing aptamers for therapeutics 
applications, with the foci on 1) the development of a AuNP based assay to study 
peptide-aptamer interaction, 2) the modification of aptamer to tailor drug delivery to 
cancer cells (but not macrophages), and 3) the study of bladder cancer cell specific 
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Cancer is the second largest non-communicable disease in the world, and accounts for 
an estimated 7.8 million deaths (or 13.7% of total deaths) in 2008, exceeded only by 
cardiovascular diseases (Butler, 2011). For men, lung and bronchus cancer has the 
highest occurrence and fatality rate worldwide among the cancer incidents; for 
women, breast cancer holds the top position (American Cancer Society, 2011b). The 
current treatment for cancer mainly involves surgical removal of tumor, radiotherapy 
and/or chemotherapy (American Cancer Society, 2011b). Surgical procedure alone is 
usually insufficient for the recovery of the patient, as residual cancer cells may still be 
present. Hence, radiotherapy and/or chemotherapy are often used in parallel. However, 
both radiotherapy and chemotherapy are not cancer cell specific, leading to the killing 
of both normal and cancer cells. This results in unwarranted side effects and lowers 
the quality of life of patients. 
 
Hence, the search is on for the “magic bullet”, a concept established by Paul Ehrlich 
in 1897, to mean therapeutic drugs that are able to selectively kill cancer cells but 
possess minimal cytotoxicity to normal cells (Strebhardt and Ullrich, 2008). This is 
envisioned to lower the side effects experienced by the patient via reduction of 
administered dosage and normal cell damage. Since then, several target specific drugs 
are already in clinical use with many more under clinical trials (Aggarwal, 2010). 
Most of the drugs (such as rituximab for B cell targeting, and trastuzumab for human 





epidermal growth factor receptor 2 (HER2) protein targeting) are antibodies, which 
can preferentially target the cell receptors that are either present exclusively or 
overexpressed on the cancer cell surface (Aggarwal, 2010). Some limitations of 
antibodies are that they are prone to irreversible heat-induced denaturation, require 
extensive purification after antibody production by animal hosts and are expensive to 
produce (Nimjee et al., 2005).  
 
More recently, aptamers (ssDNA, RNA or peptide oligomers) that have affinity for 
their targets equal to or better than antibodies have been investigated for their 
therapeutic properties (Nimjee et al., 2005). ssDNA aptamers in particular are 
molecularly more stable than RNA (Marimuthu et al., 2012) or peptide oligomers. 
Even though aptamers show great potential, they still face challenges such as 
recognition by macrophages and short half lives in serum (especially for RNA 
aptamers) (Keefe et al., 2010). In addition, although some aptamers possess 
therapeutic properties (e.g. inhibiting cell growth and inducing cell apoptosis), others 
do not (Cerchia and de Franciscis, 2010) and thus require an additional step to 
functionalize the aptamers with drug molecules (Donovan et al., 2011).  
 
Systematic evolution of ligands by exponential enrichment (SELEX) is often used to 
select aptamers with high affinity for their targets (Stoltenburg et al., 2007) but 
numerous DNA sequences (usually ~100) are obtained after each round of selection. 
Each selection round comprises incubation of aptamer with target, followed by 
separation and amplification of target-bound aptamer. The amplified aptamers go 
through another selection round until high affinity binders for the target are obtained. 
Hence, efficient methods to assess the affinity of these sequences with their targets 





need to be developed to ascertain the effectiveness of the screening process in 
identifying high affinity binders after each selection round. 
 
One of the aptamers, MUC1 cellular protein targeting aptamer, was obtained via 
SELEX against the MUC1 conserved peptide sequence 
PDTRPAPGSTAPPAHGVTSA (Ferreira et al., 2006). MUC1 protein is 
overexpressed in the majority of the human adenocarcinomas, including breast cancer 
and bladder cancer (Ferreira et al., 2006; Jarrard et al., 1998; Taylor-Papadimitriou et 
al., 1999). While bladder cancer is only the seventh highest in terms of incident 
occurrence and ninth highest in terms for fatality for men, there is a high rate of 
reoccurrence and lack of targeting ligands for bladder cancer that can be applicable 
for various types of bladder cancers. Hence, it is imperative to study the possible 
ligands to facilitate targeted drug delivery. For breast cancer targeted therapy, 
systemic circulation of therapeutic drugs is the norm of the treatment (American 
Cancer Society, 2011a) and hence the importance of macrophage avoidance. For 
bladder cancer targeting, the therapeutic drugs will usually be directly injected into 
the bladder cavity (Prasad et al., 2011) and macrophage avoidance is not of critical 
importance. The ability to selectively target and retain the drug at the cancer site upon 
urine voiding is more crucial.  
 
1.2. Objectives and Scopes 
The main objective of this study is to use aptamer-mediated therapy to increase drug 
delivery specificity toward cancer cells. This includes developing methods to screen 
aptamers obtained from SELEX (to rapidly identify aptamers with high affinity for 
their targets), studying potential ligands for use in targeted drug therapy, and reducing 





the macrophage recognition ability of the aptamers (to prevent the aptamers from 
being eliminated by the macrophages prior to reaching the targeted site, and thus 
achieving stealth targeting). Macrophage recognition has to be considered whenever 
direct drug delivery to cancer site is not possible and systemic intravenous delivery 
has to be administered.  
 
The specific objectives and scopes of this thesis are as follows: 
 
1) To establish a facile method to identify ssDNA aptamers of high affinity for their 
targets. This is achieved by harnessing the differential affinity between ssDNA-
AuNPs, MUC1 peptide-AuNPs, and ssDNA-MUC1 peptide to modulate AuNP 
stability in the presence of ionic salt. The study of AuNP stability via the 
consequential color change is the basis of the detection. 
 
2) To investigate the targeting of MUC1 protein on cancer cells by MUC1 specific 
aptamers, and their ability to intercalate and deliver DOX to the cancer cells. The 
MUC1 specific aptamer S1.3 (APT) was modified with PEG to enhance the 
selectivity of APT for MCF7 (MUC1 overexpressing breast cancer cells) over 
macrophages.  
 
3) To enhance the selectivity of aptamer in situ during aptamer synthesis (one-step 
process) instead of post-synthesis modification with PEG (two-step process). APT 
was first truncated to retain only the loop region (termed L), and then synthesized in 
two or three repeat form (i.e. L2 and L3). The DOX intercalation ability and 
selectivity of L3 were studied in detail and compared to that of APT. 





4) To investigate the applicability of cell surface protein targeting ligands [APT, 
MUC1 antibody, epidermal growth factor receptor (EGFR) targeting RNA aptamer, 
HER2 targeting RNA aptamer and ανβ3 integrin targeting peptide aptamer] for use in 
drug delivery to bladder cancer cells (T24, UM-UC-3 and/or MGH-U3).  
 
1.3. Outline of the Thesis 
This dissertation consists of seven chapters. Chapter 1 provides the background to the 
current problems faced in cancer therapeutics, and defines the objectives and scope of 
this study to partially address the problems faced. The literatures relevant to this study 
are reviewed in Chapter 2. Chapters 3 to 6 contain the main experimental findings and 
the discussion of the study. Chapter 7 provides the recap of major conclusions and 
additional insights obtained from this study, as well as suggestions for future work. 
An overview of the investigations in this study is presented in a flowchart on page 7. 
 
In Chapter 3, AuNPs were used as colorimetric probe and fluorescence quencher for 
affinity analysis of DNA aptamers toward their target MUC1 peptide. ssDNA 
aptamer-coated AuNPs showed increased stability (i.e. more resistant to aggregation 
induced by NaCl) in the presence of their target peptide due to increase in steric 
protection conferred by the ssDNA-peptide complexes formed on the AuNPs. Based 
on changes in the UV-vis extinction spectrum of AuNPs (a measure of AuNPs 
aggregation) and fluorescence restoration of CY5-ssDNA upon ssDNA-peptide 
complex formation, the formation of the complexes and ssDNA sequence dependent 
dissociation constant were determined. Besides the UV-vis and fluorescence 
measurements, the hydrodynamic diameters, zeta potential measurements and 
transmission electron microscopy (TEM) images of AuNPs after various coatings 





supported the assay principle. The methodology presented herein provides a rapid and 
sensitive solution for identification of high affinity binders from SELEX. 
 
In Chapter 4, the targeted drug delivery of DOX to MCF7 was obtained using APT as 
a carrier. The modification of the APT-DOX complex by PEG increases the 
survivability of the macrophage control (RAW 264.7) by about 6-fold as compared to 
free DOX treatment, without significantly affecting the cytotoxicity toward the target 
cell line. Thus, PEG-APT-DOX is potentially a new therapeutic agent for targeted 
drug delivery to MUC1 overexpressing cancer cell lines. 
 
In Chapter 5, APT was modified to increase its drug delivery specificity toward 
MCF7. The active targeting region of APT was truncated and variable repeats (one, 
two or three) of this sequence were synthesized. An aptamer formed from three 
repeats of this active targeting region (L3) was shown to possess enhanced DOX 
intercalation ability, and L3-DOX complex exhibited selective cytotoxicity to MCF7 
over RAW 264.7 macrophages. Most importantly, L3 was able to evade the 
macrophages (2-fold reduction in L3 uptake relative to APT), thus resulting in an 
overall 5.5-fold increase of survivability of RAW cells as compared to when free 
DOX was used. These results indicate that aptamer L3 has good potential for targeted 
drug therapeutics.  
 
Currently, there is limited information in the literature on targeting ligands for 
specific bladder cancer drug delivery. Hence, in Chapter 6, the properties of several 
reported targeting ligands for bladder cancer was investigated specifically for their 
usages in drug delivery. These include APT, MUC1 antibody, EGFR targeting RNA 





aptamer (CL4), HER2 targeting RNA aptamer (mini RNA) and ανβ3 integrin 
targeting peptide aptamer (PLZ4). APT and MUC1 antibody were tested for their 
affinity against MGH-U3, a MUC1 overexpressing bladder cancer cell line. EGFR 
and HER2 targeting RNA aptamers were tested against bladder cancer cell lines, T24, 
UM-UC-3 and MGH-U3, expressing different levels of EGFR and HER2. ανβ3 
integrin targeting peptide aptamer was tested against bladder cancer cell line, T24, an 














2.1. What are Nucleic Acid Aptamers? How are the Aptamers Found? 
The term aptamer is derived from Latin word “aptus” (meaning to fit) (Ellington and 
Szostak, 1990) and Greek word “meros” (meaning a piece), i.e. a piece that fits into 
its target. Nucleic acid aptamers are ssDNA or RNA with three-dimensional structures 
that can specifically recognize their targets with high affinity in the picomolar to 
nanomolar range, similar to that of an antibody. Some advantages of aptamers over 
antibody are aptamers can be chemically synthesized, are less immunogenic than 
antibodies, are not as temperature sensitive, can be easily conjugated with fluorescent 
dyes and functional groups, and can be theoretically selected for any target including 
biologically toxic molecules (Nimjee et al., 2005).  
 
SELEX is a method developed by three independent groups (Ellington and Szostak, 
1990; Robertson and Joyce, 1990; Tuerk and Gold, 1990) to identify high affinity and 
specific binders for various targets from a large pool of potential candidates known as 
aptamer library. Ellington and Szostak (1990) demonstrated in vitro selection of RNA 
molecules that bind specifically to organic dyes; Tuerk and Gold (1990) performed in 
vitro selection of RNA molecules that bind to bacteriophage T4 DNA polymerase; 
Robertson and Joyce (1990) performed in vitro selection to identify RNA enzyme that 
specifically cleaves ssDNA. Since then, aptamers have been selected against a variety 
of targets of various molecular sizes, such as metal ions, small organic molecules, 





antibiotics and proteins (Stoltenburg et al., 2007). Some uses for the aptamers are 
purification of compounds, detection of analytes in sensors, and therapeutics. 
  
The basic principle of SELEX is illustrated in Figure 2.1 (Stoltenburg et al., 2007). 
An aptamer library consists of 1013 to 1015 different sequences of ssDNA (James, 
2000). For ssDNA SELEX processes, the ssDNA library is first incubated with the 
target. Target bound ssDNA (binders) are then separated from the free ssDNA (non-
binders), followed by elution of binders from the target and amplification through 
polymerase chain reaction (PCR). After the PCR, purification of ssDNA or strand 
separation of double-stranded DNA (dsDNA) to produce ssDNA is carried out. The 
new pool of ssDNA is used for the next round of SELEX. In between the SELEX 
rounds, the bulk affinity of the ssDNA aptamers toward the target is determined, and 
the SELEX process is terminated when the bulk affinity of ssDNA aptamers no longer 
increases with the increase in rounds. The high affinity binders are then cloned using 
the standard laboratory protocols, and sequenced. The principle for RNA SELEX 
processes is similar to that of ssDNA SELEX except that in vitro transcription of 
ssDNA and reverse transcription of RNA are essential. ssDNA library has to be 
converted into RNA library via in vitro transcription before the starting of SELEX. 
After the elution of RNA from bound target, reverse transcription (RT)-PCR has to be 
carried out to convert RNA into its complementary DNA, followed by amplification 
by PCR. The dsDNA PCR product will undergo in vitro transcription to produce RNA, 
and the RNA will then be purified and used for the next round of SELEX. The ssDNA 
or RNA sequences can then be chemically synthesized and used for further 
experiments.  
 







Figure 2.1. The principles of SELEX [reproduced from (Stoltenburg et al., 2007)]. 
 
Some critical points to take note in the SELEX include: 1) PCR amplified product 
should be carefully verified through gel electrophoresis to ensure that the dsDNA 
PCR product is of the correct nucleotide length (Marimuthu et al., 2012), 2) the 
method to prepare ssDNA should be properly verified to ensure that ssDNA (but not 
dsDNA) is produced, as dsDNA form helix structures which disrupts the ssDNA 
inherent structure and thus its target recognition ability (Marimuthu et al., 2012), 3) 
for most targets, the initial binder population is low, hence to ensure successful 
identification of high affinity binders, the presence of background binders (e.g. non-
specific binding to nitrocellulose membrane used in the selection to separate binders 
from non-binders) should be minimal, 4) the method employed for the separation of 
binders from non-binders should be efficient, and 5) the properties of the target and 





the selection conditions have to be as close as possible to the actual condition of 
aptamer use. 
 
SELEX and its modified forms have been extensively reviewed in the literature 
(Keefe and Cload, 2008; Park et al., 2012; Stoltenburg et al., 2007). Some variations 
include spiegelmer SELEX, in vivo SELEX, cell SELEX, nitrocellulose membrane 
based SELEX, FluMag SELEX, capillary electrophoresis SELEX, non-SELEX, 
electrophoretic mobility shift assay based SELEX, atomic force microscope based 
SELEX, graphene oxide assisted SELEX and surface plasmon resonance (SPR) based 
SELEX. Each method has its pros and cons, and the choice of selection method is 
highly dependent on inherent target and aptamer library properties, as well as usage 
environment of selected aptamer. For instance, for a small molecule target, it is not 
suitable to use a size dependent separation method to separate binders from non-
binders, since with or without the target, ssDNA molecular weight remains 
approximately the same. Instead, if the small molecule target is inherently fluorescent 
or could be fluorescent tagged, the one-bead-one-compound (OBOC) method could 
be used to identify the binders (Luo et al., 2008). For OBOC method, each polymer 
bead is synthesized with multiple copies of a unique ssDNA sequence, and then 
incubated with the fluorescent target. After which, the bead that exhibits fluorescence 
will be picked up using a micropipette, and the ssDNA on the bead will be eluted and 
sequenced. On the other hand, if the target is a cell surface protein, in vitro SELEX 
utilizing purified protein as target is convenient. However, there have been reports 
that the structure of the protein is different when purified as compared to in situ 
protein on the cultured cell or tumor surface, thus recently a group tested in vivo 
selection of RNA aptamers targeting hepatic colon cancer metastases in tumor-





bearing mice (Mi et al., 2010). One of the selected aptamers (identified as aptamer 14-
16) could selectively target the tumor tissue but not normal liver tissue. This provides 
a proof of concept study that highlights the feasibility of in vivo SELEX as a method 
to select ligands binding to extracellular cell receptors in their native conditions.  
 
2.2. Current Methods for Determining Affinity of Selected ssDNA or 
RNA Aptamer Sequences for Their Targets 
There are various methods to determine the bulk affinity of aptamers in between 
selection rounds and affinity of selected aptamer sequences for their targets (Jing and 
Bowser, 2011). These include nanoparticle-based affinity assay (Merkoci, 2010), 
nitrocellulose filter binding (Tang et al., 2007), electrophoretic mobility shift assay 
(Hellman and Fried, 2007), capillary electrophoresis (Yunusov et al., 2009), SPR 
(Homola, 2008), and isothermal titration calorimetry (Neves et al., 2010). 
Nanoparticle-based affinity assay utilizes the nanoparticle’s optical, electrical or 
magnetic property for analysis of the interaction between the aptamer and its target 
(Merkoci, 2010). For instance, the AuNPs exhibit size-dependent colorimetric 
changes (Mayer and Hafner, 2011) and distance-dependent fluorescence quenching of 
fluorophore (Chhabra et al., 2009), both of which could be harnessed in the design of 
affinity analysis assay (refer to Section 2.3 for detailed discussion on properties of 
AuNPs and their usage in analyte-target affinity assay). AuNPs could also facilitate 
the bridging of the gap between two electrodes, resulting in measurable conductivity 
changes (Park et al., 2002). In this method, the gap between the two electrodes 
contained immobilized target. The AuNPs modified with affinity ligands to the target 
were added, and the target-ligand interaction resulted in the deposition of AuNPs in 





between the two electrodes. This together with the deposition of silver on the AuNPs 
resulted in measurable conductivity changes.  
 
For nitrocellulose filter binding assay (Tang et al., 2007), the aptamers are first end 
labeled with [γ-32P] adenosine triphosphate. The labeled aptamers are then incubated 
with the target, and the mixture filtered through the nitrocellulose membrane. The 
aptamer-target complexes are retained on the nitrocellulose filter, whereas the 
unbound aptamers collected as the filtrate. The retained aptamers are quantified using 
a radioactivity counter.  
 
For electrophoretic mobility shift assay (Hellman and Fried, 2007), either agarose or 
native polyacrylamide gel could be used, though polyacrylamide gel offers better 
resolution for protein-aptamer complexes of molecular weight less than 500000 (Fried, 
1989). The separation of protein-aptamer complexes from free aptamers is based on 
charge and size. A small and highly negative charged compound will migrate faster 
toward the positive electrode under the electric field. Hence, this method is suitable if 
the target has a high molecular weight and/or positive charge such that it will 
retard/shift the aptamer band, and allow the protein-aptamer complex band to be 
identified. 
 
For capillary electrophoresis (Heiger, 2000; Yunusov et al., 2009), the aptamer is 
incubated with the target, and the mixture is then injected into the capillary tubing (in 
situ incubation of aptamer and target in the capillary tubing is also possible). An 
electric field is subsequently applied to enable the separation of free aptamer from 
aptamer-target complex. The separation could be based on several principles 





depending on the chemistry of the capillary tubing. With uncoated silica capillary 
tubing, the separation is based on electroosmotic and electrophoresis flow; with 
polyvinyl alcohol coated capillary, the separation is based on electrophoresis flow; 
with polyacrylamide gel filled capillary, the separation is based on electrophoresis 
flow and molecular size. 
 
For SPR (Homola, 2008), the smaller molecule (either the aptamer or target) will be 
immobilized on a gold chip to allow for more sensitive detection of the analyte. As 
the analyte interacts with the immobilized aptamer or vice versa, the resonance 
frequency of surface plasmon will be altered. The degree of interaction between the 
aptamer and target is then inferred from the change in resonance frequency, with 
stronger interaction exhibiting larger change in resonance frequency.  
 
For isothermal titration calorimetry (Neves et al., 2010), either the aptamer or the 
target is first injected into the isothermal titration calorimetry reaction vessel. Once 
the analyte is added, the heat emitted due to stable formation of aptamer-target 
interaction will be measured, with stronger interaction resulting in greater heat release. 
  
The method to be used is dependent on the properties and costs of targets and 
aptamers, and the environment in which the selected aptamer will be used. If the 
target is expensive, methods that require small sample volumes for each affinity assay, 
such as the capillary electrophoresis, is ideal. In addition, some assay methods will 
allow free aptamer to free protein interaction, while other methods will require either 
the aptamer or protein to be immobilized. The immobilization of molecules will 
render some functional groups of the molecules to be inactivated, and some sites of 





the molecules might be blocked and unable to interact with their targets. This is not 
important if the aptamer will be immobilized when their final usage is for detection of 
analyte in the flow solution while being immobilized on a sensor chip, e.g. in SPR. 
However, if the aptamer were to be used for free drug delivery, it would be better to 
select a method of analysis that would allow the aptamer to interact with its target 
freely in the solution. This is to ensure that the site of interaction between the aptamer 
and the target is not blocked due to the immobilization. In addition, the sensitivity of 
the assay should be in the picomolar to nanomolar level. A high sensitivity is 
especially important for monitoring the increase in bulk aptamer affinity as the 
screening proceeds. For the initial rounds, the population of binder aptamers is low 
and it is ideal to use only a small amount for affinity test such that the rest of the 
aptamers could be used for the next round of selection to maximize the sequence 
variation, and this could only be achieved if the sensitivity of the assay is high. 
 
2.3. AuNP Properties and Usages in Analyte Detection/Affinity 
Analyses 
The synthesis of AuNPs of different sizes and shapes has been reported. The 
conventional synthesis of spherical AuNPs (ca. 20 nm) is performed via citrate 
reduction of HAuCl4 in boiling water (Turkevich et al., 1951). By varying the citrate 
to HAuCl4 ratio, spherical AuNPs of different sizes (8 to 180 nm) were achieved 
(Bastus et al., 2011; Frens, 1973). The preparation of smaller AuNPs (5 to 9 nm) was 
obtained by replacing the water with deuterium oxide (Ojea-Jiménez et al., 2010). 
AuNPs of various shapes (such as rod, cube and star-shaped nanoparticles) were 
synthesized using varying ratio of HAuCl4, cetyltrimethylammonium bromide and 
ascorbic acid in water (Sau and Murphy, 2004). 





Noble metal (such as gold or silver) exhibits SPR, which is the collective oscillation 
of free electrons on the metal surface (Figure 2.2a) (Mayer and Hafner, 2011). The 
oscillating electric field of an incident optical light excites the free electrons. SPR 
occurs at the angle of incidence where the free electrons resonate with the electric 
field of the incident light. For noble nanoparticles (with diameters smaller than the 
wavelength of visible light), all the free electrons of the nanoparticles collectively 
oscillate, and this is known as localized SPR (LSPR) (Figure 2.2b) (Mayer and Hafner, 
2011). When LSPR occurs, the electric fields near the particle surface are greatly 
enhanced, and the particle optical extinction is maximal at the plasmon resonant 





Figure 2.2. a) SPR and b) LSPR [reproduced from (Mayer and Hafner, 2011)]. 
 
Spherical AuNPs of 13 nm in diameter, for instance, have maximal optical light 
absorbance at 520 nm, and thus exhibit a wine red colored suspension (Figure 2.3, 
spectrum a) (Su, 2010). As the particles aggregate due to external factors (e.g. 
increase in buffer ionic strength), the coupling of plasmon oscillation from adjacent 
particles enhance the local electric field and the maximal optical light absorbance is 
shifted to longer wavelengths. As a result, the color of the suspension changes to deep 





red, purple, blue (Figure 2.3, spectra b-d) and eventually colorless (when all particles 
are precipitated). In addition, AuNPs can quench fluorophores when the emission 
spectra of the fluorophores overlap with the LSPR spectrum of AuNPs, and the 
nanoparticles are present in close proximity to the fluorophores (up to 200 Å) 
(Sapsford et al., 2006; Singh and Strouse, 2010). This is due to the transfer of emitted 
energy from the fluorophores to the surface plasmon of nanoparticles, also known as 
nanomaterial surface energy transfer (NSET) (Griffin and Ray, 2008; Sapsford et al., 




Figure 2.3. UV-vis absorbance spectra of spherical AuNPs (13 nm) under different 
degree of aggregation, with a-d representing spectrum of increasingly aggregated 
particles [reproduced from (Su, 2010)]. 
 
The optical and NSET properties of AuNPs have been used in various colorimetric 
and fluorescence assays, respectively. For colorimetric assay, it is based on the 





different degree of nanoparticle aggregation (and hence suspension color) in buffer of 
various ionic strengths, and the modulation of the aggregation by the presence of 
ligands and analytes. For example, when two types of nanoparticles (type 1: with 
covalently immobilized ssDNA ligands; type 2: with covalently immobilized ssDNA 
complementary of type 1) were mixed together (Liu and Lu, 2006) in the absence of 
the target molecule, the ssDNA on type 1 and 2 nanoparticles interacted with each 
other and caused the particles to aggregate (purple suspension). In the presence of the 
target molecule, the ssDNA ligands on type 1 nanoparticles interacted preferentially 
with the target molecules, and thus dissociated from type 2 nanoparticles. As the 
initially aggregated nanoparticles dispersed, the color of the nanoparticle suspension 
changed from purple to red. More detailed discussions and examples are given in 
Chapter 3. In addition, the various designs of colorimetric assays are summarized in a 
book chapter by Su (2010).  
 
For fluorescence assay, it is based on the alteration of distance between AuNPs and 
fluorophores upon the ligand-analyte interaction. The fluorophore quenching ability 
of AuNP decreases as its distance from the fluorophore increases (Chhabra et al., 
2009), and thus the difference in fluorophore fluorescence intensity is used to detect 
the ligand-analyte interaction. For example, hairpin structured ssDNA was tagged at 
one end with a AuNP, and at the other end with a fluorophore (Figure 2.4) (Dubertret 
et al., 2001). Due to the close proximity of the AuNP with the fluorophore, the 
fluorescence of the fluorophore was quenched. In the presence of the complementary 
ssDNA, hybridization of the DNA strands to form dsDNA caused the fluorophore to 
extend away from the AuNP and its fluorescence was restored. More detailed 





discussions and examples will be given in Chapter 3 and is available in a review paper 




Figure 2.4. Role of NSET in the detection of target DNA using ssDNA hairpin probe 
[adapted from (Sapsford et al., 2006)]. 
 
2.4. Aptamers in Clinical Trials 
The first commercial aptamer drug pegaptanib sodium (also known as Macugen), an 
anti-vascular endothelial growth factor (anti-VEGF) RNA aptamer for treatment of 
neovascular age-related macular degeneration (AMD), was approved by US FDA in 
December 2004 (Ng et al., 2006). Since the emergence of aptamers in the 1990 
(Ellington and Szostak, 1990; Robertson and Joyce, 1990; Tuerk and Gold, 1990), no 
other therapeutic aptamer has reached the commercial market. A search for the term 
“aptamer” returned 20 results for ongoing clinical trials, whereas a search for the term 
“antibody” gave 6358 results [US National Institutes of Health 
http://www.clinicaltrials.gov (assessed 30 Mar 2012)]. Despite the advantages of 
aptamers over antibodies (as discussed in Section 2.1), the number of clinical trials for 
aptamer is only 0.3% of that for antibody. This is in part due to the patents of aptamer 





technologies being currently held by a few companies: Gilead Sciences, Inc. (Foster 
City, CA, US) holds the key patents for aptamer technologies, Archemix Corp. 
(Cambridge, MA, US) holds a license for therapeutic applications, and SomaLogic, 
Inc. (Boulder, CO, US) holds a license for diagnostic applications (Bunka et al., 2010). 
Hence, this will limit the number of companies that can take part in the clinical trials 
for aptamers. Given the small number of clinical trials, the pharmacokinetics and 
pharmacodynamics of the aptamers in the human body are still relatively unknown as 
compared to that of the widely studied antibodies. In addition, the cost for large-scale 
production of aptamers with the current available technologies is still high (Esposito 
et al., 2011a). All these might contribute to the reason why few companies are 
currently involved in the aptamer therapeutics clinical trials. Nevertheless, the total 
global market value for nucleic acid aptamers is expected to reach US$1.9 billion in 
2014, with US$1.2 billion from therapeutics applications [BCC Research 
http://www.bccresearch.com (assessed 30 Mar 2012)]. This shows that aptamer 
therapeutics has a great potential despite the current problems faced which limit the 
number of the large-scale aptamer clinical trials. 
  
Out of the twenty known aptamer clinical trials (Table 2.1), seven are for potential 
cancer therapeutics applications with two main aptamers involved (i.e. AS1411 and 
NOX-A12). AS1411, developed by Antisoma Research, is a guanine-rich (G-rich) 26-
mer ssDNA (5′-GGTGGTGGTGGTTGTGGTGGTGGTGG-3’) (Bates et al., 2009). 
Due to the G-rich sequence, it forms quadruplex DNA structure, which enables 
enhanced cellular uptake and nuclease-resistance. AS1411 targets nucleolin which is a 
protein overexpressed by various cancer cells both intracellularly and on the cell 
surface. AS1411 is an antiproliferation cancer drug that shows cell growth inhibition 





in various cancer cells including breast, ovarian, leukemia, prostate, glioma and lung 
cancers. It is currently under three clinical trials for metastatic renal cell carcinoma 
(phase II), advanced solid tumors (phase I, completed), and acute myeloid leukemia 
(phase II, completed) (Table 2.1). NOX-A12, developed by NOXXON Pharma AG, is 
a 45-mer L-RNA linked to 40 kDa PEG (Sayyed et al., 2009). NOX-A12 targets 
stromal cell-derived factor-1 (SDF-1) and thus inhibits SDF-1 binding to chemokine 
receptors. This is conducive for reduction of cell resistance to chemotherapeutics drug, 
angiogenesis, tumor growth and metastasis (in cancer therapeutics), and for stem cell 
mobilization (in stem cell transplantation). It is currently under four clinical trials for 
multiple myeloma (phase II), chronic lymphocytic leukemia (phase II), hematopoietic 
stem cell transplantation (phase I, completed), and autologous stem cell 
transplantation (phase I, completed) (Table 2.1).  
 
Other aptamers under clinical trials include aptamers for blood anticoagulation 
(ARC1779, REG1), blood procoagulation (ARC19499), AMD (ARC1905, E10030, 
EYE001, pegaptanib sodium), hippel-lindau disease (EYE001), diabetic macular 














Table 2.1. Active aptamer clinical trial details and status [US National Institutes of 
Health http://www.clinicaltrials.gov (accessed 30 Mar 2012)]. * indicates potential 
cancer therapeutic drug. 
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Table 2.1. (continuation from page 22) Active aptamer clinical trial details and status 
[US National Institutes of Health http://www.clinicaltrials.gov (accessed 30 Mar 
2012)]. * indicates potential cancer therapeutic drug. 
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2.5. Aptamers that can Target Extracellular Membrane Protein on 
Cancer Cells 
Several aptamers used for targeting extracellular membrane protein on cancer cells 
are listed in Table 2.2. These include aptamers targeting EGFR (Esposito et al., 
2011b), HER2 (Kim and Jeong, 2011), human epidermal growth factor receptor 3 
(HER3) (Chen et al., 2003), MUC1 (Ferreira et al., 2006), nucleolin (Bates et al., 
2009), prostate-specific membrane antigen (PSMA) (Lupold et al., 2002), protein 
tyrosine kinase 7 (Shangguan et al., 2008), and tenascin-C (Hicke et al., 2001). The 
aptamers were selected via SELEX processes using either purified proteins or tumor 
cells as targets.  
 
The aptamers are used as therapeutic drugs (Bates et al., 2009; Chen et al., 2003; 
Esposito et al., 2011b), tools for targeted drug delivery and/or tools for targeted 
imaging and detection (via attachment of fluorescent dyes, magnetic nanoparticles, 
gold nanoparticles or quantum dots to the aptamers) (Cerchia and de Franciscis, 2010). 
EGFR RNA aptamer (CL4) (Esposito et al., 2011b), HER3 RNA aptamer (A30) 
(Chen et al., 2003) and nucleolin aptamer (AS1411) (Bates et al., 2009) were shown 
to be potential therapeutic drugs for cancer therapy. EGFR RNA aptamer (CL4) was 
shown to induce apoptotic cell death in vivo in A549 lung cancer cell-mouse 
xenografts (Esposito et al., 2011b). After treatment with CL4 for 16 days, the tumor 
growth was inhibited by 57%, as compared to that treated by a scrambled control 
sequence of CL4 (CL4sc). HER3 RNA aptamer interacted with oligomeric form of 
HER3 extracellular membrane protein (Chen et al., 2003). In the absence of heregulin, 
HER3 self-associates to form homodimer (Sliwkowski et al., 1994). With heregulin,   
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HER3 preferentially forms dimer with HER2 and promotes cell growth (Sliwkowski 
et al., 1994). A30 inhibited heregulin-dependent tyrosine phosphorylation of HER2 
and the heregulin-induced growth response of MCF7 breast cancer cells (Chen et al., 
2003). The addition of A30 even at high concentrations of heregulin (100 nM) results 
in a 50% inhibition of heregulin-induced cell growth of MCF7 cells. Nucleolin 
ssDNA aptamer exhibited growth inhibition of various human malignancies including 
breast, ovarian, leukemia, prostate, glioma and lung cancer (Bates et al., 2009). It is 
currently under three active clinical trials (refer to Section 2.4 for more details). 
 
Although not all aptamers possess inherent therapeutic properties, the selected 
aptamers with affinity for their targets can be easily modified with drug molecules. 
The aptamer-drug complex/conjugate could then be used for targeted drug therapy. 
For instance, MUC1 ssDNA aptamers were conjugated to radionuclides for in vivo 
radiotherapy and diagnostic imaging of cancer (Borbas et al., 2007), and conjugated 
to paclitaxel loaded poly (lactic-co-glycolic-acid) nanoparticle for targeted paclitaxel 
drug delivery to MCF7 breast cancer cells (Yu et al., 2011). PSMA RNA aptamer was 
conjugated to polyethyleneimine-PEG, followed by DOX intercalation within the 
polymer-RNA complex, to form nanoparticles for targeted DOX delivery to prostate 
cancer cells (Kim et al., 2010b). PSMA RNA aptamer was also conjugated to PEG 
coated Fe3O4 nanoparticle, followed by DOX intercalation within the nanoparticle, for 
prostate cancer therapy and imaging (Wang et al., 2008).  
 
In addition, the aptamers could also be used for detection of cancer cells alone. An 
aptamer targeting human acute lymphoblastic leukemia cells was linked to AuNPs for 
the direct colorimetric detection of the cancer cells (Medley et al., 2008). The 





aptamers presented in Table 2.2 could also be modified with a fluorescent dye to 
enable cell imaging or disease diagnosis.   
 
2.6. Importance of Macrophage Evasion in Drug Delivery 
The mononuclear phagocytic system consists of monocytes, macrophages and 
dendritic cells (Chow et al., 2011). Monocytes are generated by haematopoietic stem 
cells in the bone marrow and released into blood circulation (Murray and Wynn, 
2011). Some monocytes are stored in the spleen reservoir, while others extravasate 
through the endothelium and differentiate into macrophages or dendritic cells 
(Geissmann et al., 2010). The primary roles of monocytes are to remove blood 
pathogens and replenish tissue-resident macrophages or dendritic cells (Murray and 
Wynn, 2011). Macrophages capture and clear apoptotic cells and cell debris (Chow et 
al., 2011). Macrophages also capture and clear opsonized pathogens, and secrete 
cytokines to recruit leukocytes during infections (Chow et al., 2011). Dendritic cells 
capture opsonized pathogens and present antigens to T cells, thereby initiating T cell 
mediated cell killing of foreign pathogens (Chow et al., 2011).  
 
The major macrophage locations in different parts of the body and some of their site-
specific functions are presented in Figure 2.5 (Murray and Wynn, 2011). These 
include dermis macrophage, splenic macrophage, intestinal macrophage, subcapsular 
sinusoidal macrophage, medullary macrophage, osteoclast, Kupffer cell, alveolar 
macrophage, intraoccular macrophage and microglia. For example, osteoclast is 
responsible for bone resorption, Kupffer cell is for clearance of pathogens and toxins 
from the liver, and alveolar macrophage is for elimination of allergens from the lung.  
 







Figure 2.5. The various functions of tissue macrophages [reproduced from (Murray 
and Wynn, 2011)]. 
 
For intravenous drug delivery, the therapeutic molecule has to avoid macrophage 
recognition to prevent premature clearance of the therapeutic molecule from the blood 
stream (i.e. before the drug can reach the diseased site) (Moghimi et al., 2001). 
Opsonin proteins in the blood stream (such as immunoglobulin G and complement 
activation fragments) bind to foreign pathogens and enhance their recognition (and 
thus clearance) by macrophages (Murray and Wynn, 2011). Hence, one method to 
avoid rapid macrophage clearance is to reduce non-specific adsorption of opsonin 
proteins on the therapeutic molecule. The adsorption of proteins is dependent on 
surface charge, hydrophobicity, size and shape of the molecule; uncharged, 
hydrophilic and small particles (< 100 nm) are less likely to be detected by 
macrophages (Aggarwal et al., 2009; Vonarbourg et al., 2006). Drug molecules and 





nanoparticles for drug delivery are often modified with polysaccharides (dextran, 
chitosan and heparin) (Lemarchand et al., 2004) and polymers (especially PEG) 
(Aggarwal et al., 2009; Owens and Peppas, 2006; Vonarbourg et al., 2006) to 
decrease binding of opsonin proteins. PEG is hydrophilic, uncharged, non-
immunogenic and biocompatible (Gref et al., 1995). The widespread use of PEG is a 
combination of its favorable macrophage evading properties, and the commercial 
availability of PEG with various functional groups to facilitate its attachment to drug 
molecules or nanoparticles (e.g. PEG-thiol could be used for immobilization of PEG 
on AuNPs, and PEG-carboxyl could be used for attachment of PEG to molecules with 
amine functional groups). 
 
2.7. Breast Cancer: Current Treatment Methods and Limitations 
Breast cancer is the most common cancer for women, and claims the most lives 
among all cancers (American Cancer Society, 2011b). The current breast cancer 
treatment includes various combinations of surgery, radiation therapy and/or 
systemically administered therapy (targeted therapy, chemotherapy and hormone 
therapy) (American Cancer Society, 2011a).  
 
The primary objectives of surgery are to remove cancerous tissue, and collect tissue 
samples for disease typing (American Cancer Society, 2011a) in order to determine 
the most efficient treatment method. The types of surgery available are lumpectomy 
(removal of cancerous tissue together with normal tissue in the immediate 
surrounding), simple mastectomy (removal of entire breast), modified radical 
mastectomy (removal of entire breast and lymph nodes under the arm), and radical 





mastectomy (similar to modified radical mastectomy except with the inclusion of 
underlying chest wall muscle removal) (American Cancer Society, 2011a).  
 
Radiation therapy consists of external beam radiation and internal radiation (also 
known as brachytherapy) (American Cancer Society, 2011a). The external beam 
radiation is the conventional method whereby radiation from an external machine is 
focused outside the body at the area affected by cancer. This is repeatedly performed 
over a period of 5 to 6 weeks. Internal radiation involves sealing a radioactive 
substance in wires or catheters, and placing them directly at or near the cancer site.  
 
Systemically administered therapy before surgery is known as neoadjuvant therapy, 
whereas that performed after surgery is known as adjuvant therapy (American Cancer 
Society, 2011a). The former is to shrink the tumor before surgery to allow for less 
extensive surgery, while the latter is to eliminate any residual tumor cells from the 
body to decrease risk of cancer recur. Systemically administered delivery is also used 
for metastatic breast cancer where surgery is not possible due to extensive spread of 
the disease. Chemotherapy is being used for breast cancer where targeting ligands to 
specific overexpressed receptors on the cancer cell surface is not available. It is 
usually a combination of cyclophosphamide, methotrexate, fluorouracil, DOX, 
epirubicin, paclitaxel and docetaxol. Hormone therapy is either to prevent estrogen 
from binding to hormone-receptor-positive breast cancer cells or to lower estrogen 
levels (in postmenopausal women). This is because estrogen binding to hormone 
receptors on breast cancer cells promotes cancer growth. Tamoxifen and toremifene 
prevent estrogen from binding to hormone receptor. Aromatase inhibitors (such as 
letrozole, anastrozole and exemestane) lower the estrogen levels. 





Targeted therapy utilizes a targeting ligand with specific affinity for an overexpressed 
receptor on the cancer cell to reduce cell growth. About 20-30% of breast cancers 
overexpress HER2 (Slamon et al., 1987). These tumors grow more rapidly and are 
more likely to recur. Herceptin is a monoclonal antibody that targets HER2 receptors, 
and is used for the treatment of HER2-positive breast cancer (Slamon et al., 2001). 
Another drug, Tykerb, is a small molecular tyrosine kinase inhibitor that is used to 
treat HER2-positive breast cancer resistant to herceptin (Geyer et al., 2006). In 
addition, several new aptamer ligands were reported to target MUC1 protein (Ferreira 
et al., 2006), HER2 (Kim and Jeong, 2011) and HER3 (Chen et al., 2003) 
overexpressed on some breast cancer cells. However, these aptamer ligands are only 
at the pre-clinical trial stage.   
 
2.8. Bladder Cancer: Current Treatment Methods and Limitations 
Bladder cancer is the seventh most common cancer for men (American Cancer 
Society, 2011b). It is classified mainly as transitional cell carcinoma, squamous cell 
carcinoma and adenocarcinoma based on the type of cell in which the cancer 
originates (GuhaSarkar and Banerjee, 2010). Transitional cell carcinoma forms the 
majority of the bladder cancer occurrences. Out of all the newly diagnosed cases 
across the classifications, 70% is non-muscle-invasive while 30% is muscle-invasive 
(Prasad et al., 2011), with the muscle-invasive cancer being associated with a poor 
survival rate (Howlader et al., 2011). It is also the most expensive cancer to treat 
based on cost per patient (Botteman et al., 2003), largely due to the high recurrence 
rate and lifelong surveillance requirement.  
 





The current bladder cancer treatment includes transurethral resection, intravesical 
therapy [Bacillus Calmette-Guerin (BCG) therapy and intravesical chemotherapy], 
radical cystectomy, pelvic lymphadenectomy and systemic chemotherapy 
(neoadjuvant and adjuvant chemotherapy) (Prasad et al., 2011). Transurethral 
resection is usually first performed to remove superficial tumors, and tumor tissue for 
disease staging in order to determine the appropriate therapy. 
 
For non-muscle-invasive bladder cancer, intravesical drug delivery is the standard 
treatment protocol (GuhaSarkar and Banerjee, 2010). The urinary bladder wall is 
protected by umbrella cells joined by tight junctions (Lewis, 2000), plaque proteins 
(Kong et al., 2004; Lewis, 2000; Yu et al., 1994) and a hydrophilic mucin layer 
(Poggi et al., 2000; Soler et al., 2008). These mechanisms serve well to prevent the 
toxins from the urine from reentering the bloodstream. In intravesical drug delivery, 
BCG  or chemotherapeutic drugs (such as DOX, gemcitabine, epirubicin, mitomycin 
C, thiotepa, and cisplatin) (Shen et al., 2008) are delivered directly to the urinary 
bladder via the urethra using a catheter (GuhaSarkar and Banerjee, 2010). Although 
intravesical drug delivery allows high concentration of therapeutic drug to be 
delivered to the cancer site with minimal systemic side effects, the drug needs to be 
frequently re-administered. This is because drug concentration tends to be diluted by 
the urine, and the drug removed through urine voiding. In addition, the same 
mechanism that serves to protect the body from the toxins in the urine is also 
preventing the therapeutic drugs from entering the cancer site. To counter these 
problems, 1) mucoadhesive polymers (e.g. chitosan) or nanoparticles could be used 
for drug delivery so that the drug would be retained at the bladder wall despite urine 
voiding (GuhaSarkar and Banerjee, 2010), 2) targeting ligands could be utilized to 





specifically target bladder cancer site and retain the drug at the bladder cancer site 
(Black et al., 2007), and 3) permeation enhancers (e.g. application of electromotive 
force, using of chemicals such as chitosan and dimethyl sulfoxide to disrupt the 
protective bladder wall cells) could be used to enhance drug uptake efficacy 
(GuhaSarkar and Banerjee, 2010; Shen et al., 2008). Currently, there are no known 
targeting ligands for in situ bladder cancer cell targeting. However, there are several 
reports in the literature of antibodies and aptamers (Black et al., 2007; Esposito et al., 
2011b; Hughes et al., 2000; Zhang et al., 2012) that could potentially be used for in 
situ bladder cancer cell targeting (refer to Chapter 6 for more details on the targeting 
ligands).  
 
For muscle-invasive bladder cancer, radical cystectomy (removal of the entire bladder 
and neighboring tissues/organs including prostate in men, and the uterus, ovaries and 
cervix in women) is the standard treatment procedure (Prasad et al., 2011). In addition, 
pelvic lymphadenectomy is often performed at the time of radical cystectomy to 
increase the survival rate of patients, with the number of nodes removed ranging from 
10-14 (Herr et al., 2002; Herr, 2003; Konety et al., 2003; Stein and Skinner, 2005). 
Muscle-invasive bladder cancer has a high probability of developing into metastatic 
bladder cancer. For metastatic bladder cancer, radical cystectomy together with 
neoadjuvant and/or adjuvant chemotherapy is the recommended treatment (Grossman 
et al., 2003). The drugs used in the chemotherapy are cocktails of methotrexate, 
vinblastine, DOX, cisplatin and gemcitabine (Prasad et al., 2011). However, cisplatin 
faces a limitation that it cannot be administered to patients with impaired renal 
function (Prasad et al., 2011), and systemic chemotherapy is not an effective therapy 





for bladder cancer due to low drug uptake efficacy at cancer site on urothelial wall 



























AFFINITY ANALYSIS OF DNA APTAMER-PEPTIDE 
INTERACTIONS USING GOLD NANOPARTICLES 
  
3.1. Introduction 
Since hundreds of aptamer sequences are generated with each round of SELEX 
(Gopinath, 2007), a rapid and cost efficient way to screen for their relative affinity is 
essential. As mentioned in Section 2.2, there are many platforms that can screen for 
ssDNA or RNA aptamers with affinity for a variety of targets including protein 
biomarkers and small molecules (Gopinath, 2007; Jing and Bowser, 2011). Several 
techniques, such as capillary electrophoresis, SPR and column affinity-based methods, 
require either expensive instruments or tedious probe immobilization. Besides these 
techniques, AuNPs are also widely used as colorimetric sensing platform for detecting 
a wide range of biomolecular binding and biological processes based on the control of 
nanoparticle aggregation and dispersion (Ling and Huang, 2010; Liu et al., 2007; 
Zhao et al., 2008a). The aggregation of AuNPs results in a red shift of the UV-vis 
absorption spectrum, giving rise to purple, blue or grey suspensions depending on the 
degree of aggregation (Su, 2010). More details of AuNP properties and a brief 
introduction to AuNP usages in analyte detection/affinity analyses have been given in 
Section 2.3.  
 
It is well known that ssDNA can physically adsorb onto AuNPs and thus stabilizes the 
AuNPs electrostatically in salt solution, while dsDNA and structured DNA (formed 
by ssDNA upon ligand binding) do not; the differential binding of ssDNA and 





dsDNA/structured DNA toward AuNPs has been used in various colorimetric assays 
for detecting DNA sequence and DNA binding molecules. In the detection of 
thrombin (37 kDa) (Wei et al., 2007), kanamycin (Song et al., 2011), oxytetracycline 
(Kim et al., 2010c) and potassium ion (Wang et al., 2006), ssDNA with affinity for 
their respective target molecules were first coated onto the AuNPs which prevented 
the aggregation of AuNPs in the presence of NaCl. In the presence of the target 
molecules, the ssDNA dissociated from the AuNP surface in favor of the ssDNA-
target molecule complex formation, resulting in the removal of electrostatic protection 
by ssDNA and subsequent aggregation of AuNPs in salt solution. The affinity ratio 
between aptamer-AuNP and aptamer-target (i.e. Kd AuNP/Kd target) determines the 
sensitivity of the assay, with higher affinity ratio giving a more sensitive assay (Kim 
et al., 2011). The concept that ssDNA and structured DNA exert differential 
protection to AuNPs, however, has been rarely applied for the detection of peptides, 
but is mostly used for the detection of small molecules (Song et al., 2011; Wang et al., 
2007; Wang et al., 2006). 
 
In addition to its interparticle distance-determined plasmonic coupling property, 
AuNPs have the ability to quench fluorescent dyes that are in close proximity via 
NSET (Singh and Strouse, 2010) as discussed in Section 2.3. The distance-dependent 
fluorescence quenching ability of AuNPs has been used for sensing various molecules 
(Jin et al., 2009), studying RNA folding mechanism (Griffin and Ray, 2008) and 
detecting single-base mismatch in DNA (Dubertret et al., 2001; Niu et al., 2011). As 
the distance of the fluorescent dye molecule from the AuNP surface increases (either 
via ligand displacement from the particle surface or ligand conformational change in 
the presence of target analyte), the restoration of dye fluorescence will occur.    





Herein, using the LSPR and NSET properties of AuNPs, we developed an assay that 
can be conveniently used for the identification of aptamer sequences with high 
affinity for their target. A 40-amino-acid-long peptide (i.e. two repeats of the 20-
amino-acid-long variable tandem repeat region of MUC1 protein, 
PDTRPAPGSTAPPAHGVTSA) and its ssDNA aptamers of different affinity 
(Ferreira et al., 2006) were used as the model samples to develop our assay. MUC1 
protein is overexpressed by the majority of human adenocarcinomas and has been 
associated with poor cancer prognosis (Jarrard et al., 1998). The assay is based on the 
observation that in the presence of target MUC1 peptide, the stability of the ssDNA-
coated AuNPs (ssDNA-AuNPs) was increased (i.e. more resistant to aggregation 
induced by NaCl), and the quenched fluorescence of CY5 (where CY5-labeled 
aptamer was used) was restored. The formation of ssDNA-peptide complexes and 
their binding affinity was measured using the corresponding colorimetric change and 
fluorescence emission. The covalent immobilization of ssDNA onto AuNPs prior to 
the assay is not required, and the assay can be completed within minutes. To our 
knowledge, this is the first work to illustrate that the dissociation of ssDNA from the 
AuNP surface by targeting molecules (as reported in the literature (Song et al., 2011; 
Wang et al., 2006; Wei et al., 2007)) is not a prerequisite for the AuNP-based assay to 
work, i.e. the retention of formed ssDNA-peptide complex on the AuNP surface can 
also be used for molecular detection/interaction study at equivalent sensitivity. 
 
3.2. Experimental Section  
3.2.1. Materials  
HAuCl4•3H2O (99.99%) (520918) and trisodium citrate dihydrate (99.9%) (S4641) 
were purchased from Sigma-Aldrich, Singapore. The 40-amino-acid-long peptide, 





PDTRPAPGSTAPPAHGVTSA PDTRPAPGSTAPPAHGVTSA (Ferreira et al., 
2006), was synthesized by GL Biochem, Shanghai. Aptamers with high targeting 
efficacy toward MUC1 (umAPT: unmodified ssDNA sequence S1.3, 5’-
GCAGTTGATCCTTTGGATACCCTGG-3’) and lower targeting efficacy toward 
MUC1 (umAPT2: unmodified ssDNA sequence S1.1, 5’-
TAAGAACAGGGCGTCGTGTTACGAG-3’) (Ferreira et al., 2006), unmodified 
ssDNA library comprising a mixture of 25 mer random sequences (umLIB), and their 
5’ CY5-C6 spacer-labeled counterparts were synthesized by Integrated DNA 
Technologies (IDT), Singapore.   
 
3.2.2. Preparation of citrate-coated AuNPs  
Citrate-coated AuNPs of 13 nm in diameter were prepared by the citrate reduction of 
HAuCl4 (Tan et al., 2010). The citrate anions play a dual role as both reducer and 
stabilizer in the process of AuNP formation (Parab et al., 2007). The excess citrate 
stabilizes the AuNPs by forming a complex multilayered assembly of anions of 
various oxidation states on the AuNP surface. An aqueous solution of sodium citrate 
(5 ml, 40 mM) was added rapidly to a boiling solution (100oC) of HAuCl4 (50 ml, 1 
mM). Within several minutes, the color of the solution changed from pale yellow to 
red. The mixture was further heated at 100oC under reflux for 30 min to ensure 
complete reduction of HAuCl4. The UV-vis absorbance of the AuNPs was measured 
at 520 nm. The concentration of the AuNPs was calculated to be 11 nM using Beer’s 









3.2.3. Colorimetric assay procedure 
The AuNP suspension was used without further purification. Seventy microliters of 
the AuNP suspension were incubated with 10 µl of water and 10 µl of unmodified 
ssDNA aptamer at various concentrations (giving final assay concentrations of 1000 - 
0 nM, with the actual experimental conditions indicated in the respective figure 
legends) in water to form ssDNA-AuNPs. Ten microliters of MUC1 peptide at 
various concentrations (giving final assay concentrations of 1000 - 0 nM) in binding 
buffer (0.2 M NaHCO3, 0.5 M NaCl, pH 7.4) were then incubated with the ssDNA-
AuNPs (giving a final assay concentration of 50 mM NaCl). All incubation steps were 
carried out for 10 min. As a control, a mixture of 70 µl of AuNP suspension and 30 µl 
of water was used. After incubation, the UV-vis absorbance of the suspension was 
read from 400 nm to 800 nm using a microplate reader (Powerwave XS, Bio-tek). 
 
3.2.4. Fluorescence assay procedure  
The experimental protocol was similar to the Colorimetric Assay Procedure, except 5’ 
CY5-labeled ssDNA aptamers were used and the fluorescence was read at excitation 
wavelength of 600 nm and emission wavelength of 630 nm to 750 nm using a 
fluorescence microplate reader (Tecan infinite M200). 
 
3.2.5. Characterization 
Dynamic light scattering (DLS) and zeta potential measurements were performed 
using the Zetasizer Nano ZS (Malvern) with a disposable cuvette (DTS 1060C) as the 
solution carrier. Each experiment was carried out with three replicates (n = 3) and the 
data is presented as mean ± standard deviation. All data were analyzed using the two-
sample t-test with p < 0.05 considered as significant. TEM images of AuNPs were 





recorded on a transmission electron microscope (JEM-2010, JEOL) at an accelerating 
voltage of 200 kV. The sample for TEM was prepared by dispensing 20 µl of particle 
suspension onto a carbon-coated copper grid followed by air-drying.   
 
3.3. Results and Discussion 
The selection of aptamers with affinity for MUC1 peptide was performed at pH 7.4 
(Ferreira et al., 2006). A change in buffer condition (e.g. pH and salt concentration) 
may reduce the aptamer-peptide interaction. Hence, the assay was conducted at pH 
7.4 to maintain the affinity between the aptamers and the peptide. The principle of the 
assay used in this work is based on the differential effect of ssDNA-peptide complex 
on AuNP stability against salt-induced aggregation, relative to ssDNA and peptide 
alone. It is therefore essential to first investigate the interaction of the individual 
entities (ssDNA, peptide, and their complexes) with the AuNPs.  
 
3.3.1. Interaction of ssDNA with AuNPs  
The AuNPs prepared by the citrate reduction of HAuCl4 are partially coated with 
citrate anions which render the surface negatively charged, and thus these 
nanoparticles disperse well in water (Parab et al., 2007). The remaining uncoated 
regions of the nanoparticles are the hydrophobic gold surfaces (Nelson and Rothberg, 
2011). At a certain threshold salt (e.g. NaCl) concentration, the electrostatic repulsion 
between negatively charged AuNPs is screened by the positive Na+ ions. This allows 
the AuNPs to move closer to one another and results in aggregation of the 
nanoparticles via hydrophobic (between regions of AuNPs that are not coated with 
citrate) and van der Waals forces. Since negatively charged ssDNA is known to have 
a strong affinity for AuNPs, it can protect the particles against salt-induced 





aggregation (Li and Rothberg, 2004). The details of the interaction mechanism 
between the ssDNA and AuNPs will be discussed in Section 3.3.4.  
 
Figure 3.1a shows the UV-vis absorption spectra of AuNPs after preincubation with 
umAPT at different concentrations (giving a final assay concentration of 1000, 500, 
250, 125, 63, 31, 16 or 0 nM), and followed by addition of binding buffer (giving a 
final assay concentration of 50 mM NaCl). Without the addition of umAPT, AuNPs 
largely aggregated in the binding buffer, as seen by the disappearance of absorption 
peak at 520 nm and the increased absorption at longer wavelengths. The protection 
effect of ssDNA in preventing the aggregation of AuNPs can be observed at ssDNA 
concentration as low as 63 nM (dotted orange line) with a peak at 520 nm in its 
absorption spectrum. At ssDNA concentration of 1000 nM (solid black line), the 
AuNPs remain largely dispersed similar to that in water. The higher peak intensity (in 
the presence of 1000 nM of ssDNA as compared to AuNPs in water) at 520 nm is due 
to the adsorption of ssDNA on AuNP surface which changes the surface plasmon 
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Figure 3.1. UV-vis absorbance spectra of a) AuNPs after preincubation with umAPT 
(from top to bottom: 1000, 500, 250, 125, 63, 31, 16, 0 nM) in water, followed by 
subsequent binding buffer addition and b) AuNPs after addition of MUC1 peptide 
(from top to bottom: 1000, 500, 250, 125, 63, 31, 16, 0 nM) in binding buffer. The 
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3.3.2. Interaction of MUC1 peptide with AuNPs  
Several amino acids in proteins or peptides (such as cysteine (C), histidine (H), 
arginine (R) and lysine (K)) are known to interact with negatively charged citrate-
coated AuNPs (Tan et al., 2010; Zubavichus et al., 2004). Cysteine (C) is known to 
interact with AuNPs via the gold-thiol bond formation, histidine (H) via the imide 
group, and the basic amino acid residues such as arginine (R) and lysine (K) via 
electrostatic interactions. The 40-amino-acid-long peptide used in this study contains 
four residues in the peptide that may interact with the AuNPs (i.e. two R residues with 
pKa = 12.0 and two H residues).  
 
Figure 3.1b shows the UV-vis absorption spectra of AuNPs after preincubation with 
peptide at different concentrations (giving a final assay concentration of 1000, 500, 
250, 125, 63, 31, 16 or 0 nM) in binding buffer (giving a final assay concentration of 
50 mM NaCl). The interaction of this peptide with AuNPs was observed by peptide-
mediated protection of AuNPs at concentrations of 500 nM (dashed blue line) and 
above. At concentrations of 250 nM and below, no peptide-mediated protection was 
detected. The fact that this peptide offers much less protection against AuNP 
aggregation relative to ssDNA at the same concentration (ssDNA at 63 nM shows 
substantial protection) is likely due to the peptide [pI of 7.3, calculated using ExPASy 
Bioinformatics Resource Portal, Swiss Institute of Bioinformatics 
http://web.expasy.org/compute_pi (accessed 14 Oct 2012)] being only slightly 
negatively charged at the assay pH of 7.4 and also being of smaller molecular weight 
than ssDNA (peptide MW of 3756 compared to ssDNA MW of 7843). Hence, the 
peptide coating offers less charge repulsion and/or steric hindrance that are essential 
for AuNP stabilization (Su, 2010).  





3.3.3. Detection of ssDNA-MUC1 peptide complex formation and measurement 
of binding affinity using AuNPs  
In Figure 3.1, it is shown that ssDNA aptamers and their target MUC1 peptide offer 
different degrees of protection against AuNP aggregation in terms of the 
concentration required. Herein, the effect of ssDNA-peptide complex formation on 
the stability of the AuNPs was investigated. The AuNPs were first incubated with 
umAPT at selected concentrations (at a final assay concentration of 125, 250 or 500 
nM) followed by the addition of peptide in binding buffer (at a final assay 
concentration of 250, 125, 63, 31, 16, 8 or 0 nM peptide with 50 mM NaCl). When 
the peptide was incubated with the ssDNA-coated AuNPs, the particle aggregation 
was retarded (Figures 3.2a-c). The details of how the ssDNA-peptide complex 
formation on AuNP surface retards the AuNP aggregation will be discussed in Section 
3.3.4. To quantify the extent of aggregation, the ratio of absorbance at 700 nm over 
that at 520 nm (A700/A520) was used. This is because the peak at 520 nm is expected 
to be reduced and the absorbance at 700 nm increased with particle aggregation (Li 
and Rothberg, 2004). As shown in Figure 3.2d, as the peptide concentration increases, 
the degree of aggregation decreases (i.e. A700/A520 ratio decreases). The values 
obtained were fitted to a linear regression and the R2 values for the AuNPs 
preincubated with 125, 250 and 500 nM ssDNA were 0.86, 0.99 and 0.91, 
respectively. The gradients of the fitted lines were -8.36 × 10-4, -6.89 × 10-4 and -1.17 
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Figure 3.2. UV-vis absorbance spectra of AuNPs after preincubation with umAPT in 
water using a) 125, b) 250 or c) 500 nM ssDNA, followed by addition of different 
concentrations of MUC1 peptide (from top to bottom: 250, 125, 63, 31, 16, 8, 0 nM) 
in binding buffer. The UV-vis absorbance spectra of AuNPs in water and binding 
buffer (black solid line) are shown as controls; d) Ratio of UV-vis absorbance 
































125 nM umAPT 
250 nM umAPT 
500 nM umAPT 
250 nM Peptide 
125 nM Peptide 
63 nM Peptide 
31 nM Peptide 
16 nM Peptide 
8 nM Peptide 
0 nM Peptide 
AuNPs in buffer 
AuNPs in water 





Considering the R2 values and the sensitivity (defined as change in A700/A520 ratio 
as the peptide concentration changes), 250 nM was selected as the optimal 
concentration of ssDNA to use for the study of ssDNA sequence dependent aptamer-
peptide affinity. At the optimal ssDNA concentration of 250 nM, the change in 
A700/A520 ratio is observed at as low as 8 nM MUC1 peptide, showing that this 
could be used as a method to study the interaction between MUC1 peptide and the 
ssDNA. The limit of detection for MUC1 peptide using this newly developed method 
is comparable or lower than in the detection assays where the interaction of target 
molecule and AuNP surface bound ssDNA causes ssDNA to be dissociated from the 
AuNP surface, e.g. 8.33 nM for the detection of thrombin protein (Wei et al., 2007), 
10 nM for kanamycin (Song et al., 2011), and 1.67 mM for potassium ion (Wang et 
al., 2006). In addition, the limit of detection of MUC1 peptide in our assay is also 
lower than quantum dot-based detection of the same MUC1 peptide (where the 
detection limit was 250 nM) (Cheng et al., 2009).  
 
In Figure 3.3a, 250 nM (final assay concentration) of umAPT (aptamer with high 
affinity for MUC1 peptide), umAPT2 (aptamer with lower affinity for MUC1 peptide) 
(Ferreira et al., 2006) or control umLIB was mixed with AuNPs. In each of the 
ssDNA-AuNP suspensions, MUC1 peptide of 250, 125, 63, 31, 16, 8 or 0 nM (final 
assay concentration) in binding buffer (with a final assay concentration of 50 mM 
NaCl) was added. Similar protection behavior was observed for umAPT, umAPT2 
and umLIB (i.e. similar A700/A520 ratio when only binding buffer was added), 
showing that ssDNA binding to AuNPs is not sensitive to DNA sequence. The 
greatest stabilization effect (i.e. the lowest A700/A520 ratio) was observed for 
umAPT followed by umAPT2 and umLIB at a peptide concentration of 250 nM. 










Figure 3.3. a) Ratio of UV-vis absorbance (A700/A520) of AuNPs after 
preincubation with ssDNA (250 nM of umAPT, umAPT2 or umLIB) in water, 
followed by addition of MUC1 peptide (250, 125, 63, 31, 16, 8, 0 nM) in binding 
buffer; b) Determination of Kd from relative UV-vis absorbance (A700) of AuNPs 
after preincubation with ssDNA (250 nM of umAPT, umAPT2 or umLIB) in water, 
followed by addition of MUC1 peptide (250, 125, 63, 31, 16, 8, 0 nM) in binding 
buffer. For b), the lines were fitted using the Langmuir model with initial 
concentration of peptide as the x-axis (peptide was present in excess and thus initial 
concentration was approximated as equilibrium concentration). 
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This is likely due to the different degree of interaction between the umAPT, umAPT2 
or the umLIB and the MUC1 peptide, i.e. the higher the affinity, the larger the extent 
of ssDNA-peptide complex formation. The three-dimensional structure of the 
complexes results in more steric protection than if either ssDNA or peptide alone is 
present. 
 
As A700 decreased with increasing peptide concentration, the Langmuir curve 
(usually shown by an increase of adsorbed analyte as analyte concentration increases) 
could not be fitted. Hence, the relative value of A700 was used instead for the fitting 
of the Langmuir curve (i.e. by mirroring the value for A700 along the x axis or y'(x) = 
y(0) - y(x) where y'(x) is the new y value of A700 at x nM peptide, y(0) is the original 
y value of A700 at 0 nM peptide, y(x) is the original value of A700 at x nM peptide 
and x = 250, 125, 63, 31, 16, 8 or 0) (Figure 3.3b). The relative dissociation constants 
(Kd) for each of the three cases (umAPT, umAPT2 and umLIB) were 207 nM, 227 
nM and 3.69 mM with R2 of 0.94, 0.98 and 0.95, respectively. The original Kd values 
of umAPT and umAPT2 (with the highly immunogenic epitope, APDTRPAPG, of 
MUC1 protein as target) were reported as 0.135 nM and 33.38 nM, respectively 
(Ferreira et al., 2006). In our study, to mimic better the presentation of MUC1 protein 
on cellular surface (which exists as variable repeats of 20-amino-acid sequence 
containing the highly immunogenic epitope), we used two repeats of the 20-amino-
acid sequence PDTRPAPGSTAPPAHGVTSA. Hence, the extra amino acid 
sequences as well as the different method employed (SPR vs. AuNP-based assay) 
may contribute to the differences in affinity calculated. However, the trend of affinity 
for the target remains to be in descending order: umAPT, umAPT2, followed by 
umLIB.  





3.3.4. Proposed mechanisms for interaction between ssDNA physically adsorbed 
on AuNPs and MUC1 peptide 
There are three competing forces behind the assay developed in the current work, 
ssDNA-peptide, peptide-AuNP and ssDNA-AuNP interactions. These interactions are 
dependent on the native charges of the AuNP, ssDNA and peptide. The interaction 
between ssDNA and AuNP is believed to arise from coordination chemistry (Wang et 
al., 2006) and/or hydrophobic interaction (Nelson and Rothberg, 2011) of exposed 
nitrogen base rings with the citrate-depleted regions of AuNP surface. Highly 
negatively charged citrate-coated AuNPs tend to repel negatively charged ssDNA but 
this is overcome by the interaction forces between the exposed AuNP surface (i.e. 
regions not coated by citrate) and nitrogen base rings of ssDNA. ssDNA is known not 
to displace citrate anions from the AuNPs, instead it causes the enhancement of 
negative charges on the AuNP surface (Li and Rothberg, 2004; Nelson and Rothberg, 
2011). Protein/peptide molecules enriched with cysteine (due to presence of thiol), 
histidine, and/or basic residues such as arginine or lysine (Tan et al., 2010; 
Zubavichus et al., 2004) are likely to interact with AuNP with the avidity of 
interaction increasing as the number of residues with these properties increases. 
 
The formation of the ssDNA-peptide complex changes the conformation of the 
ssDNA and/or peptide which increases the steric protection against AuNP aggregation 
(Su, 2010). This hypothesis, as illustrated in Figure 3.4, was proven with CY5-labeled 
APT, APT2 and LIB. As shown in Figure 3.5a, the fluorescence of CY5-labeled 
ssDNA is quenched in the presence of AuNPs due to the overlap of the 
photoluminescence spectrum of CY5 and the LSPR band of AuNPs (Singh and 
Strouse, 2010). The efficient quenching indicates that the ssDNA is coated on the 





AuNP surface. However, in the presence of the target peptide, the fluorescence 
emissions from CY5 of the APT and APT2 increase, indicating that the distance of 
CY5 molecule from the AuNP surface increases due to the formation of peptide-CY5 
ssDNA complex (Chhabra et al., 2009). In addition, as shown from Figure 3.5b, the 
increase in fluorescence is largest for APT, followed by APT2 and LIB. Since the 
stability of ssDNA-AuNPs increase in the presence of peptide, this shows that the 
complexation of peptide and CY5 ssDNA does not cause the ssDNA to leave the 
particle surface (as this would result in AuNPs aggregation instead of AuNPs 
disaggregation (Li and Rothberg, 2004)). Hence, taking into consideration the 
fluorescence restoration and particle stability in salt solution, the mechanism in Figure 




Figure 3.4. Illustration of the assay principle presented in the current study. AuNPs 
coated with CY5-labeled ssDNA (fluorescence quenched) tend to aggregate in NaCl 
due to partial screening of negative charges of both citrate and ssDNA by NaCl 
(shown as pink AuNPs to indicate a more aggregated state) (Route A). Binding of 
peptide with ssDNA will enhance the stability of AuNPs in salt solution via steric 
hindrance and at the same time emit fluorescence due to the formation of ssDNA-
peptide complex (Route B).   
 
 
The peptide-CY5 ssDNA complex that is formed still remains on the AuNP surface, 
due to the presence of free nitrogen base rings that are still available despite the 
complex formation, and the formation of the complex introduces conformational 
changes that cause the fluorophore to extend away from the AuNP surface. The  










Figure 3.5. a) Fluorescence spectra of CY5-APT (250 nM) in the presence of AuNPs, 
and in the presence of both AuNPs and MUC1 peptide (250 nM) in binding buffer 
and b) Relative fluorescence intensity of CY5-labeled ssDNA (250 nM of either CY5-
APT, CY5-APT2 or CY5-LIB) in the presence of AuNPs and MUC1 peptide (250, 
125, 63, 31, 16, 8, 0 nM) in binding buffer. The fluorescence intensity of CY5-LIB-
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maximum possible extension of CY5 dye molecule from the AuNP surface was 
estimated to be 16.9 nm (sum of 15.8 nm for the contour length of 25 mer ssDNA 
(Shroff et al., 2005) and 1.1 nm for the C6 spacer from the ssDNA to the center of 
CY5 dye molecule (Chhabra et al., 2009)). The actual extension of CY5 dye from the 
AuNP surface, however, is expected to be less than 16.9 nm due to the fact that some 
of the nucleotide bases will be involved in AuNP/peptide binding and that the ssDNA 
is not stretched under high mechanical forces (as in the determination of the ssDNA 
contour length). While Förster resonance energy transfer is limited to the study of 
interaction between two molecules at distances less than 10 nm, NSET is suitable for 
distances up to 20 nm (Griffin and Ray, 2008; Ling and Huang, 2010).  
 
The mechanism proposed herein is in contrast to a previously reported study on the 
detection of thrombin using thrombin protein targeting aptamer (Wei et al., 2007). In 
that study, the 29 mer ssDNA aptamer formed a complex with thrombin, resulting in 
the dissociation of aptamer from the AuNP surface. The elimination of aptamers from 
AuNP surface reduced the stability of AuNPs in the presence of NaCl, resulting in 
AuNP aggregation. Thrombin is a protein which is approximately 10 times larger (37 
kDa) compared to the peptide used in this study (3.8 kDa). The larger protein may 
provide more sites for aptamer binding and hence has a higher propensity to 
dissociate the aptamers from the AuNPs. In addition, in the presence of thrombin, the 
aptamer is known to fold into a structure of G-quadruplex (Tasset et al., 1997), thus 
causing the aptamer to leave the AuNP surface.  
 
On the other hand, AuNPs modified with ssDNA aptamers via gold-thiol bonding 
showed higher salt stability in the presence of their respective target (either adenosine 





or potassium ion) (Zhao et al., 2008b). The greater stability of the AuNPs is endowed 
by the three-dimensional structural change of the aptamer in the presence of its target, 
and hence providing more electrostatic (via increase of exposed surface negative 
charges from the ssDNA phosphate backbone) or steric hindrance between the 
individual AuNPs. This is consistent with the observation in the current chapter (i.e. 
in the presence of MUC1 peptide, the stability of the aptamer-modified AuNPs 
increases), except that in the current study it was shown that the increase in AuNP 
stability is possible even without the anchoring of ssDNA via the gold-thiol bonding 
and steric hindrance is the main stabilization factor. 
 
The aggregation of the particles under various experimental conditions was further 
confirmed and the assay mechanism validated by DLS measurement of hydrodynamic 
size, zeta potential measurement of surface charge and TEM images. From the DLS 
data (Figure 3.6), it can be seen that peptide-affinity aptamer (umAPT or umAPT2) 
complexes rendered the particles less prone to aggregation in salt solution compared 
to the case where peptide or ssDNA existed alone. For instance, AuNPs preincubated 
with 250 nM of peptide only were precipitated in salt solution (similar to when no 
peptide coating was employed, Figure 3.1b) while umAPT-coated AuNPs aggregated 
to a lesser extent and exhibited a hydrodynamic diameter of 77.2 ± 5.1 nm (the 
hydrodynamic diameter of dispersed AuNPs in the absence of NaCl was 20.2 ± 0.3 
nm). In the presence of both peptide and umAPT, a smaller hydrodynamic diameter of 
36.5 ± 0.1 nm was obtained. A similar trend in hydrodynamic diameters of AuNPs 
was observed for umAPT2, i.e. largely reduced hydrodynamic diameter (less 
aggregation) for AuNPs with umAPT2-peptide complex compared to AuNPs with 
umAPT2 alone. In the case of umLIB, the presence of peptide did not significantly 





stabilize the ssDNA-AuNPs. The aggregate size (78.0 ± 1.2 nm with peptide) 




Figure 3.6. Hydrodynamic diameter of AuNPs in various conditions obtained using 
DLS technique. AuNPs W: AuNPs in water; umAPT W: 250 nM umAPT in water; 
PEP B: 250 nM MUC1 peptide in binding buffer; AuNPs umAPT W: AuNPs 
preincubated with 250 nM umAPT in water; AuNPs umAPT B: AuNPs preincubated 
with 250 nM umAPT in water, followed by incubation with binding buffer; AuNPs 
umAPT PEP B: AuNPs preincubated with 250 nM umAPT in water, followed by 
incubation with 250 nM MUC1 peptide in binding buffer. Experimental conditions 
involving umAPT2 and umLIB follow similar legend explanations as that for umAPT. 
* denotes significant difference (p < 0.05, n = 3) as compared to the result obtained 









































































































The zeta potential of umAPT-AuNPs was -37.7 ± 0.6 mV without the peptide and -
33.1 ± 1.5 mV with the peptide. The slight reduction of zeta potential, i.e. the 
decrease in surface exposed negative charges, indicates the formation of the ssDNA-
peptide complex. The peptide of near neutral charge could have shielded the negative 
charge from the phosphate backbone of ssDNA, thereby reducing the surface exposed 
negative charges. On the other hand, no surface charge difference was observed for 
the umLIB-AuNPs before (-36.4 ± 0.9 mV) and after the addition of peptide (-36.4 ± 
2.2 mV). This indicates that there is no substantial complex formation. The ssDNA-
peptide complex formation causes the increased stability of AuNPs in salt condition 
despite the reduction in surface potential. This observation strongly supports our 
speculation that steric forces exerted by the complexes endowed higher stability to the 
AuNPs.  
 
TEM images showed the aggregation of AuNPs in the presence of peptide alone in 
binding buffer (Figure 3.7a) and the disaggregation of AuNPs in the presence of 
ssDNA-peptide complex in binding buffer (Figure 3.7d). Figures 3.7b and 3.7c show 
the TEM images of umAPT-coated AuNPs in water and binding buffer, respectively. 
All these results support the mechanism shown in Figure 3.4 that the formation of 
peptide and umAPT or umAPT2 complexes can reduce the particle aggregation 
through the effect of increased steric hindrance, as the zeta potential does not increase 
in negativity but the aggregate size is reduced. 
 







Figure 3.7. TEM images of a) AuNPs preincubated with 250 nM MUC1 peptide in 
binding buffer (AuNPs PEP B), b) AuNPs preincubated with 250 nM umAPT in 
water (AuNPs umAPT W), c) AuNPs preincubated with 250 nM umAPT in water, 
followed by incubation with binding buffer (AuNPs umAPT B), and d) AuNPs 
preincubated with 250 nM umAPT in water, followed by incubation with 250 nM 















3.4. Summary  
The advantages of using AuNPs for affinity analysis include the ease of AuNPs 
synthesis and rapid analysis process (requiring approximately 20 min in this study). 
The assay developed in this study facilitates a simple and fast assessment of the 
relative affinity of SELEX-based screened aptamers to their targets. The aptamers 
could be either a pool of SELEX-enriched aptamers of unknown sequences or 
individual aptamers of known sequences (obtained after SELEX via standard ssDNA 
cloning, sequencing and chemical synthesis). In the former, the determination of bulk 
affinity is to ensure that with each round of selection, the number of aptamers with 
specific affinity for the target increases (i.e. aptamers binding to background matrix 
are not amplified instead). In the latter, the determination of individual aptamer 
affinity is to identify a specific high affinity binder for the target. The differences in 
interaction mechanism between ssDNA and AuNPs, peptide and AuNPs, and the 
conformational change of ssDNA and/or peptide after ssDNA-peptide complex 
formation made it possible to use the AuNPs for ssDNA-peptide affinity study. 
However, it is necessary to conduct a preliminary study to determine the interaction 
between the ssDNA and peptide with AuNPs. One limitation of this method is that 
this assay may be invalid for target peptide or protein that interacts strongly with the 
AuNPs (e.g. those with multiple C, H, R or K residues). For these cases, a coating of 
passivating polymer (e.g. silica) may be necessary to prevent or modulate the 
interaction of peptide/protein with the AuNPs. The ssDNA target can then be 
immobilized onto the polymer for use in the detection of target. Nevertheless, the 
simple method presented here is expected to be applicable in other conditions. 
 
 






PEGYLATED MUCIN 1 APTAMER-DOXORUBICIN 
COMPLEX FOR TARGETED DRUG DELIVERY TO 
MCF7 BREAST CANCER CELLS 
 
4.1. Introduction 
To counter or reduce the adverse side effects of anti-cancer drugs used in 
chemotherapy, much attention has been devoted to the development of targeted drug 
therapy in recent years. Targeted drug therapy is achieved through drug with inherent 
targeting properties or modification of the drug molecule with a ligand that can 
selectively recognize its target. Some problems frequently encountered in targeted 
drug therapy include stability of the targeting ligand, decrease in targeting efficacy of 
the ligand, and decrease in drug efficacy in cell killing or growth retardation after 
ligand modification. Examples of targeting ligands include biomolecules (ssDNA, 
RNA, peptides, antibodies) (Cerchia and de Franciscis, 2010; Courtenay-Luck and 
Epenetos, 1989; Kunz et al., 2006) and small chemical molecules (folic acid, 
methotrexate) (Kohler et al., 2006; Sudimack and Lee, 2000). The aptamers under 
clinical trials were discussed in Section 2.4, with AS1411 and NOX-A12 for cancer 
treatment. In Section 2.5, aptamers that can target extracellular membrane proteins on 
cancer cells (and thus potentially applicable for the targeted drug delivery to cancer 
cells) were discussed. 
 





Targeted drug delivery of DOX using RNA aptamer A10 as carrier (through 
intercalation of DOX with the RNA aptamer) has been reported for prostate cancer 
(Bagalkot et al., 2006; Farokhzad et al., 2006; Wang et al., 2008). Therapeutic 
aptamer or protein alone is often not sufficiently stable for in vivo delivery, and hence 
it is commonly PEGylated (i.e. conjugated to PEG molecule) to increase circulation 
half-life and resistance against proteases and nucleases (Veronese and Pasut, 2005). 
PEGylation may however interfere with the native structure of the aptamer or protein 
and prevent the recognition of their intended targets (Da Pieve et al., 2009).  
 
The present study reports on the use of MUC1 protein-targeting DNA aptamer 
(Ferreira et al., 2006) as a carrier for DOX for targeted breast cancer treatment (refer 
to Section 2.7 for the review on current treatment methods for breast cancer and their 
limitations), and the effects of PEGylation of the aptamer on the drug cytotoxicity 
against MCF7 (MUC1 positive breast cancer cell line) and macrophages (RAW 
264.7). The use of MUC1-targeting aptamer has been reported in a number of 
applications such as for radio diagnostics after conjugation of the aptamer with 
MAG2-99mTc tag (Pieve et al., 2009), for labeling of MUC1 positive cells with 
aptamer-modified quantum dots (Cheng et al., 2009), and for killing of MCF7 cells 
after linking to the first component of complement (C1q) protein (Bruno, 2010). 
Macrophage was used as a control cell line since one of the major challenges faced in 
in vivo drug delivery is rapid drug elimination from the bloodstream by the 
mononuclear phagocyte system (more details on the importance of macrophage 
evasion in drug delivery are given in Section 2.6). In brief, the rapid clearance of 
drugs by the mononuclear phagocyte system prevents them from reaching the target 





cells. Hence, drugs that can target cancer cells while evading macrophages would be 
highly promising.  
  
4.2. Experimental Section 
4.2.1. Materials  
1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC HCl) (E6383), N-
hydroxysuccinimide (NHS) (56480), and doxorubicin HCl (DOX) (44583) were 
purchased from Sigma-Aldrich, Singapore. Dicarboxyl PEG polymer (denoted as 
PEG, MW 3500, A4004) was purchased from Jenkem Technology, USA. MUC1-
targeting DNA aptamers (5’CY5-GCAGTTGATCCTTTGGATACCCTGG-3’ (CY5-
APT) or 5’NH2-C6 spacer-GCAGTTGATCCTTTGGATACCCTGG-3’ (APT)) were 
synthesized by IDT, Singapore. Low molecular weight DNA ladder (N3233S) was 
obtained from New England BioLabs, USA. 
 
4.2.2. Cell culture  
MCF7 (HTB-22) and RAW 264.7 mouse macrophage cells (TIB-71) (American Type 
Culture Collection, ATCC) were cultured in cell growth medium consisting of high 
glucose Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal 
bovine serum and 100 U/ml penicillin-streptomycin. The cell cultures were 
maintained at 37oC under a humidified atmosphere of 5% CO2. 
 
4.2.3. Intercalation of DOX with MUC1-targeting aptamer (APT) 
The aptamer-doxorubicin complex (APT-DOX) was prepared by intercalation of the 
APT with DOX. DOX (1.5 µM) was incubated with renatured APT at molar ratios of 
0, 0.01, 0.03, 0.1, 0.3, 0.5, 1, 3, 5, 7 and 10 in phosphate-buffered saline (PBS) buffer 





of pH 7.4 for 10 min. Fluorescence spectra of the solutions were obtained at an 
excitation wavelength of 480 nm and emission wavelength of 520-680 nm on a 
microplate reader (Tecan infinite M200). Each experiment was carried out with three 
replicates (n = 3) and the data is presented as mean (for fluorescence spectra) or mean 
± standard deviation (for Hill plot).   
 
4.2.4. Synthesis of PEG-modified MUC1-targeting aptamer (PEG-APT and 
PEG-APT-DOX)  
PEG, 400 mM EDC HCl and 100 mM NHS in water were mixed at various ratios and 
incubated for 15 min at 80 rpm on a rotamixer (SLRM-2M, Intelli-mixer MyLab). 
APT or a mixture of APT and NaCl of either 0.5, 1 or 1.5 M in 10 mM HEPES (pH 6) 
was then added, and the reaction continued for 4 h at 80 rpm. Prior to incubation with 
the cells, the mixture was dialyzed against PBS buffer (pH 7.4) for 24 h using a 
snakeskin pleated dialysis tubing (molecular weight cut off of 10000 Da) (68100, 
Thermo Scientific) to remove unreacted PEG, EDC HCl and NHS. To prepare PEG-
APT-DOX complex, PEG-APT was renatured, quantified by UV at 260 nm (UV-
1601, Shimadzu) and incubated with DOX (5.5 µM PEG-APT to 5 µM DOX) for 10 
min.  
 
4.2.5. Agarose gel electrophoresis  
Gel electrophoresis was carried out using 2% agarose gel in 0.5× tris-borate-EDTA 
buffer at 100 V for 1 h (Mini-Sub Cell GT Systems, Bio-Rad). This was followed by 
post-staining in Gel Red DNA staining solution (41003, Biotium) for 30 min and 
imaged with Gene Genius Bio-imaging system (SynGene). The percentage of aptamer 





covalently bound to PEG was analyzed from the gel image using GeneTools 
(SynGene).  
 
4.2.6. Cell cytotoxicity assay (MTT)  
MCF7 and RAW 264.7 mouse macrophage cells were seeded in a 96-well plate at 104 
cells per well (200 µl). The cells were incubated at 37oC with 5% CO2 for 24 h and 
then washed once with cell growth medium (200 µl). The cells were incubated with 
APT (5.5 µM, 100 µl), DOX (5 µM, 100 µl), APT-DOX (prepared using 5.5 µM APT 
to 5 µM DOX, 100 µl) or cell culture medium (100 µl) for 4 h. The APT, DOX, APT-
DOX complex or cell culture medium was then replaced by fresh cell culture medium 
and the MTT assay was conducted after another 1 or 3 days of cell growth. For the 
MTT assay, Thiazolyl Blue Tetrazolium Bromide (M2128, Sigma-Aldrich) was 
dissolved in PBS buffer (pH 7.4) at 5 mg/ml, and then diluted using cell culture 
medium to 0.5 mg/ml. Thiazolyl Blue Tetrazolium Bromide (0.5 mg/ml, 100 µl) was 
added to each well and incubated at 37oC with 5% CO2 for 2 h. The solution was then 
removed and dimethyl sulfoxide (100 µl) added to solubilize the formazan crystals. 
After 15 min of incubation, the absorbance was read using a microplate reader 
(Powerwave XS, Bio-tek) at 570 nm. The cytotoxicity of the PEG-APT-DOX 
complex against MCF7 and RAW cells was evaluated in a similar manner. Each 
experiment was carried out with three replicates (n = 3) and the data is presented as 
mean ± standard deviation. All data were analyzed using the two-sample t-test with p 









4.2.7. Fluorescence microscopy  
MCF7 and RAW 264.7 mouse macrophage cells were seeded in a 24-well plate at 5 × 
104 cells per well (1 ml). The cells were incubated at 37oC with 5% CO2 for 24 h and 
then washed once with cell growth medium (1 ml). CY5-APT was renatured in PBS 
buffer (pH 7.4) using the following protocol: heated to 94oC at 2.5oC/s, held at 94oC 
for 5 min, cooled to 20oC at 0.1oC/s and held at 20oC for 5 min (My Cycler PCR, Bio-
Rad) immediately before use. The cells were incubated with CY5-APT (500 nM) in 
cell growth medium (400 µl per well) at 37oC with 5% CO2 for 1 h. After incubation, 
the cells were washed thrice with PBS buffer (pH 7.4, 1 ml), fixed in 2% 
formaldehyde in PBS buffer (pH 7.4, 1 ml) for 30 min, washed with PBS buffer (pH 
7.4, 1 ml), and stored in PBS buffer (pH 7.4). Imaging was carried out with a 
fluorescence microscope (Nikon A1R) using CY5 filter and bright field.   
 
4.2.8. DOX release from PEG-APT-DOX or APT-DOX complex  
DOX (31 µM) was incubated with either renatured PEG-APT or APT at a molar ratio 
of 1.1 in PBS buffer of pH 7.4 for 10 min. The resultant PEG-APT-DOX or APT-
DOX complex was transferred to a snakeskin pleated dialysis tubing (molecular 
weight cut off of 3500 Da) (68035, Thermo Scientific) and dialyzed against PBS 
buffer of pH 7.4. After 2, 4, 6, 12, 24, 48 and 72 h, the dialysis buffer was collected 
for fluorescence intensity analysis using a microplate reader at excitation wavelength 
of 480 nm and emission wavelength of 600 nm (Tecan infinite M200), and replaced 
with fresh buffer. Free DOX (31 µM) was also dialyzed under the same condition as a 
control. Each experiment was carried out with three replicates (n = 3) and the data is 
presented as mean ± standard deviation.   
 





4.3. Results and Discussion 
4.3.1. Study of MUC1-targeting aptamer selective interaction with MCF7 cells 
using fluorescence microscopy 
The selective interaction between the MUC1-targeting aptamer and MCF7 cells is 
illustrated in Figure 4.1 using the CY5-modified aptamer (CY5-APT). Strong 
fluorescence signal was observed for MCF7 (Figure 4.1a) but not for the RAW cells 
(Figure 4.1c). This indicates that the MUC1-targeting aptamer could potentially serve 




Figure 4.1. Fluorescence and bright field microscopy images of MCF7 [a) and b)] 
and RAW cells [c) and d)] after incubation with CY5-APT.  
 
4.3.2. Intercalation efficacy of DOX with MUC1-targeting aptamer 
DOX, an anthracycline antibiotic, is a drug commonly used in cancer therapeutics. 
DOX’s cytotoxicity is achieved via the intercalation of cellular DNA preferentially at 
its double-stranded 5’-GC-3’ or 5’-CG-3’ sequences (Chaires et al., 1990). The most 
serious side effect of this drug is dose-dependent irreversible cardiotoxicity which 
may result in premature heart failure especially in the young, elderly, and those with 





predisposed health problems (Christiansen and Autschbach, 2006). The MUC1-
targeting aptamer possesses two guanine-cytosine (GC) bonds as predicted by the 
Mfold program (Zuker, 2003) (Figure 4.2). After 10 min incubation of APT with 
DOX, at an APT to DOX molar ratio of 1.1 to 1, the inherent fluorescence of DOX 
reached a minimum equivalent to that of a buffer blank (Figure 4.3a), indicating the 
successful intercalation of DOX within the two GC bonds of the aptamer. A low 
dissociation constant value of 260 nM is obtained from the Hill plot at 600 nm (Figure 
4.3b). The low dissociation constant contributes to fast and strong association 
between the aptamer and DOX even under biological salt condition (~ 137 mM NaCl). 
In comparison, the dissociation constant between PSMA RNA aptamer and DOX is 
reported as 600 nM (Bagalkot et al., 2006). The stronger interaction between DNA 
aptamer targeting MUC1 and DOX may give rise to better cell-specific drug delivery 
(due to reduced dissociation of aptamer and DOX during the delivery process) or to 
compromised cell cytotoxicity since DOX may be too tightly bound to assert its effect 
on the cells. 
 
 
Figure 4.2. Two-dimensional secondary structure of MUC1-targeting aptamer 
predicted using Mfold program (Zuker, 2003). 
 










Figure 4.3. Interaction of APT with DOX. a) Fluorescence spectra from top to bottom 
of the figure correspond to molar ratios of aptamer to 1.5 µM DOX of 0, 0.01, 0.03, 
0.1, 0.3, 0.5, 1, 3, 5, 7 and 10, and b) Hill plot obtained with fluorescence intensity 
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4.3.3. Cell cytotoxicity of APT, DOX, and APT-DOX complex 
The cytotoxicity of free APT, free DOX and APT-DOX complex against MCF7 and 
RAW cells are compared in Figure 4.4. The MTT assay was carried out after 4 h of 
incubation with APT, DOX or APT-DOX complex, and after another 3 days of 
incubation with fresh cell growth medium. The incubation of cells with APT does not 
affect the cell viability (% viable cells ~ 100%). The intercalation of DOX with APT 
does not significantly affect the drug cytotoxicity against MCF7 cells (viability of 
27.8% and 28.9% for DOX and APT-DOX, respectively) whereas the cytotoxicity 
against RAW cells is decreased by about three-fold (viability of 12.7% and 40.9% for 
DOX and APT-DOX, respectively). These results indicate that APT-DOX can 
preferentially target MUC1-expressing MCF7 cells due to the targeting property 
endowed by APT. However, the APT-DOX complex appears to retain some non-
specific targeting or immunogenic property as indicated by the significantly lower 




Figure 4.4. MTT assay of MCF7 or RAW cells after 4 h incubation with DOX, APT, 
APT-DOX, PEG-APT, PEG-APT-DOX or cell growth medium (pH 7.4) as control, 
followed by another 3 days of cell growth. * denotes significant difference (p < 0.05, 
n = 3) as compared to the result obtained with DOX under the similar condition.  
 

























4.3.4. Synthesis of PEG-modified MUC1 targeting aptamer (PEG-APT and PEG-
APT-DOX), and study of their cell cytotoxicity 
In order to increase the viability of the non-targeted RAW cells, APT was modified 
with PEG. PEG is non-toxic, non-immunogenic and FDA approved (Veronese and 
Pasut, 2005). The conjugation of PEG to drugs has been shown to increase the 
residence time of the drug in body and decrease degradation by metabolic enzymes 
(Veronese and Pasut, 2005). PEG has also been reported to reduce non-specific 
uptake of iron oxide nanoparticles by RAW cells (Xie et al., 2007). The various 
parameters that may affect PEGylation of the aptamer include PEG to aptamer molar 
ratio, ionic strength, EDC HCl and NHS concentrations, and reaction time. In this 
work, excess EDC HCl and NHS were used to eliminate them as limiting factors and 
their concentrations were kept constant to prevent changes in pH and ionic strength. 
APT to PEG molar ratio was varied as follows: 1:1, 1:20, 1:40 and 1:60, and agarose 
gel electrophoresis was used to determine the extent of reaction (Figure 4.5a). Upon 
successful conjugation of APT to PEG, the aptamer band will shift to a higher 
molecular weight position. For APT to PEG ratios of 1:1, 1:20, 1:40 and 1:60, the 
extent of APT conjugated was 0, 55.3, 73.0 and 89.2%, respectively. A further 
increase of APT to PEG ratio to 1:100 resulted in no further enhancement in the 
conjugation of the aptamer. At the optimal APT to PEG ratio (1:60), various 
concentrations of NaCl were added (0, 0.5, 1 and 1.5 M). However, the PEGylation of 
APT did not show substantial variation in this range of NaCl concentration (89.2, 88.8, 
87.8 and 86.3%, respectively). At APT to PEG ratio of 1:60, the increase in reaction 
time from 4 to 24 h also did not yield a significant increase in amount of APT bound 
(i.e. 89.2% for 4 h vs. 90.3% for 24 h) (Figure 4.5b). A possible reason for the need 
for a large excess of PEG to promote the PEGylation of APT is their large molecular  
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Figure 4.5. Agarose gel electrophoresis of PEGylated MUC1-targeting aptamer. a) 
Lane 1: Low MW DNA ladder, 2: 1 µM APT in PBS buffer (pH 7.4), 3: 1:1 molar 
ratio of APT:PEG, 4: 1:20 molar ratio of APT:PEG, 5: 1:40 molar ratio of APT:PEG, 
6-9: 1:60 molar ratio of APT:PEG with 0, 0.5, 1 and 1.5 M of NaCl, respectively, b) 
Lane 1: Low MW DNA ladder, 2: 1 µM APT in PBS buffer (pH 7.4), 3: same 
condition as Lane 6 in a), 4: same condition as Lane 3 after 24 h, 5: Low MW DNA 
ladder, and c) Lane 1: Low MW DNA ladder, 2: 1 µM APT in PBS buffer (pH 7.4), 3: 
same condition as Lane 6 in a), 4: same condition as Lane 3 after dialysis against PBS 
buffer (pH 7.4), 5: Low MW DNA ladder. 





weights (3500 and 7843.2 for PEG and the aptamer, respectively), and hence the 
reaction between these molecules may be constrained by steric hindrance. As the 
molecular weights of APT and PEG-APT conjugate are close to one another, the 
separation of residual APT from the PEG-APT was not effective using dialysis 
membrane of 10000 MWCO (Figure 4.5c, lane 3 and 4). Furthermore, due to the 
similarity in the charged nature of APT and PEG-APT (PEG is neutral molecule but 
APT is highly negative charged), complete separation of APT and PEG-APT using 
other methods such as anion exchange chromatography will also be very difficult. 
Since approximately 90% of APT was conjugated to PEG (Figure 4.5c, lane 3), no 
further attempt was made to separate out the remaining 10% free aptamer. 
 
A comparison of the cytotoxicity of PEG-APT-DOX complex against MCF7 and 
RAW cells is shown in Figure 4.4. With PEG-APT-DOX, the viability of RAW cells 
is increased by about six-fold from 12.7% with free DOX to 81.0%. PEGylation 
minimizes plasma protein adsorption (McCarthy et al., 2007) and renders the PEG-
APT-DOX less susceptible to uptake by the macrophages, thereby reducing its 
cytotoxicity. Some degree of observed cytotoxicity may be due to the residual non-
PEGylated APT-DOX complex (~ 10%). For MCF7 cells, the cell viability shows 
only a slight increase from 27.8% for free DOX to 34.1% for PEG-APT-DOX, 
indicating that both APT and PEG do not significantly affect the cytotoxic effect of 
DOX on MCF7 cells. The results shown in Figure 4.4 were obtained 3 days (of 
incubation in fresh cell growth medium) after the 4 h treatment period with DOX or 
DOX complexes. When the cells were assayed after 1 day of incubation, a similar 
trend but with generally lower cytotoxicity was observed for both MCF7 and RAW 
cells (Figure 4.6). The interaction of APT with MUC1 membrane protein on MCF7 





leads to the uptake of the APT-DOX and PEG-APT-DOX complexes. The release of 
DOX from the complex in the cell is necessary to achieve cell cytotoxicity. In 
addition, DOX may also be released from the complexes into the cell culture medium 




Figure 4.6. MTT assay of MCF7 and RAW cells after 4 h incubation with DOX, 
APT-DOX, PEG-APT-DOX or cell growth medium (pH 7.4) as control, followed by 
another 1 or 3 days of cell growth. * denotes significant difference (p < 0.05, n = 3) as 
compared to the Day 1 result obtained with the respective cell line and drug/drug 
complex.  
 
4.3.5. DOX release from PEG-APT-DOX or APT-DOX complex 
The time-dependent drug release profile of DOX from APT-DOX and PEG-APT-
DOX (carried out via dialysis against PBS buffer (pH 7.4)) is shown in Figure 4.7. 
While most of free DOX (~ 90%) diffused through the dialysis membrane within 1 
day, only about 30% of DOX was released from APT-DOX complex after 3 days of 
dialysis. However, about 90% of DOX was released from PEG-APT-DOX in the 
same time duration. The modification of aptamer with PEG may alter the 3D 
conformation of the aptamer and reduce its ability to intercalate DOX. Hence, an 
accelerated release of DOX from PEG-APT-DOX was observed. The drug release 
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profile shown in Figure 4.7 serves only as a relative comparison as it was performed 
in PBS buffer of pH 7.4. In the presence of the complex cell milieu, it is possible that 




Figure 4.7. Time-dependent release of DOX from PEG-APT-DOX and APT-DOX 
complexes. Dialysis of free DOX was used as control.  
 
4.4. Summary  
The use of APT as a drug delivery vehicle to enable targeted delivery of DOX to 
MUC1-expressing MCF7 cells has been shown to be feasible in vitro. The APT-DOX 
complex enhances the viability of RAW cells without affecting the cytotoxic effect of 
DOX to MCF7 cells. The PEGylation of APT further increases the targeting efficacy 
of the aptamer by reducing the non-specific uptake of DOX by RAW cells. As a 
result, > 80% of the RAW cells remains viable after incubation with the PEG-APT-
DOX complex while > 60% of the MCF7 cells is no longer viable under the same 
conditions. Further consideration/optimization of PEG molecular weight and structure 
(e.g. linear or branched) needs to be carried out to ensure targeted drug delivery while 
minimizing toxic accumulation of drug in the kidney.  
Time/h































DESIGNER TRIDENTATE MUCIN 1 APTAMER FOR 
TARGETED DRUG DELIVERY 
 
5.1. Introduction  
In Chapter 4, it was observed that although APT increased the specific delivery of 
DOX to MCF7, its cytotoxicity toward MCF7 was only slightly higher (~ 10%) than 
that for RAW 264.7 macrophage. Hence, PEGylation of the APT was performed to 
improve the survival rate of RAW cells without significantly affecting the 
cytotoxicity toward the MCF7 cells. PEG in this case enhanced the macrophage 
evading properties of APT by 6-fold as compared with the use of free DOX. This 
however requires an additional step to functionalize the aptamer, as PEG cannot be 
attached in situ during the synthesis of the ssDNA aptamer.   
 
Aptamer modifications are often carried out to improve the targeting efficacy and 
specificity of the selected aptamers. These include chemical modification of the 
aptamer phosphate backbone (Micklefield, 2001), sugar and/or nucleobase, truncation 
of non-essential targeting regions of the aptamer, and conjugation of the aptamer with 
other molecules (Bell and Micklefield, 2009). Some examples of conjugation of 
aptamers with other molecules to increase their targeting and/or drug delivery efficacy 
are 1) chemical modification of RNA aptamer to incorporate therapeutic small 
interfering RNA (Bagalkot and Gao, 2011; Dassie et al., 2009; Zhou and Rossi, 2010; 
Zhou et al., 2011a), 2) synthesis of RNA aptamer with a 21 mer extension (and 
hybridization of the extension with its complementary strand) to allow more sites for 





DOX intercalation (Kim et al., 2010a; Lee et al., 2011), and 3) formation of DNA 
icosahedral and DNA tetramer via primer sticky ends and tetracarboxylic small 
molecule, respectively (Borbas et al., 2007; Chang et al., 2011), and 4) linking 
aptamers using PEG spacer to form multivalent aptamer with higher affinity to target 
(Mallikaratchy et al., 2011). 
 
Herein, to optimize targeted DOX delivery to MCF7 cell and minimize the adverse 
impact on the macrophage cell, APT was first truncated to produce aptamer L. 
Various repeats (one, two or three) of L were then investigated for their DOX 
intercalation ability and drug delivery specificity. This study aims to provide a facile 
method to enhance the aptamer drug delivery properties without additional chemical 
modifications such as PEGylation.  
 
5.2. Experimental Section   
5.2.1. Materials 
MUC1-targeting DNA aptamer (5’NH2-C6 spacer-
GCAGTTGATCCTTTGGATACCCTGG-3’ or APT) and their derivatives (5’NH2-C6 
spacer-GATCCTTTGGATA-3’ or L (i.e. truncated to contain only the underlined 
sequence of APT); 5’NH2-C6 spacer- GATCCTTTGGATA GATCCTTTGGATA-3’ 
or L2 (i.e. 2 repeats of L); 5’NH2-C6 spacer-GATCCTTTGGATA 
GATCCTTTGGATA GATCCTTTGGATA-3’ or L3 (i.e. 3 repeats of L)) were 
synthesized by IDT, Singapore. CY5-labeled 25 mer ssDNA library (CY5-LIB), and 
CY5-tagged aptamers (CY5-APT, CY5-L3) were also synthesized by IDT. All 
aptamers were renatured immediately before each experiment according to the 
protocol mentioned in Section 4.2.7. 





5.2.2. Cell culture 
MCF7 and RAW 264.7 mouse macrophage cells (ATCC) were cultured as stated in 
Section 4.2.2. 
 
5.2.3. Intercalation of DOX with MUC1-targeting aptamers 
The aptamer-DOX complexes (APT-DOX, L-DOX, L2-DOX and L3-DOX) were 
prepared by intercalation of the APT, L, L2 or L3 with DOX. DOX (1.5 µM) was 
incubated with renatured APT, L, L2 or L3 at molar ratios of 0, 0.01, 0.03, 0.1, 0.3, 
0.5, 1, 3, 5, 7 and 10 in PBS buffer of pH 7.4 for 10 min. Fluorescence intensity of the 
solutions were obtained at an excitation wavelength of 480 nm and emission 
wavelength of 600 nm using a microplate reader (Tecan infinite M200). Each 
experiment was carried out with three replicates (n = 3) and the Hill plot data is 
presented as mean ± standard deviation. 
 
5.2.4. Cell cytotoxicity assay 
MCF7 and RAW cells were seeded in a 96-well plate at 104 cells per well (200 µl). 
The cells were incubated at 37oC with 5% CO2 for 24 h and then washed once with 
cell growth medium (200 µl). The cells were incubated with either aptamers (5.5 µM 
APT or L3, 100 µl), DOX (5 µM, 100 µl), aptamer-DOX complexes (prepared using 
5.5 µM of the respective aptamer to 5 µM DOX, 100 µl) or cell culture medium (100 
µl) for 4 h. The aptamers, DOX, aptamer-DOX complexes and cell culture medium 
were then replaced by fresh cell culture medium and the MTT assay was conducted 
after another 1 or 3 days of cell growth according to Section 4.2.6. Each experiment 
was carried out with three replicates (n = 3) and the data is presented as mean ± 





standard deviation. All data were analyzed using the two-sample t-test with p < 0.05 
considered as significant. 
 
5.2.5. DOX release from aptamer-DOX complexes 
DOX (31 µM) was incubated with either renatured APT or L3 at a molar ratio of 1.1 
in PBS buffer for 10 min. The resultant APT-DOX or L3-DOX complexes were 
transferred to a snakeskin pleated dialysis tubing (molecular weight cut off of 3500 
Da, Thermo Scientific) and dialyzed against PBS buffer. The dialysis buffer was 
collected for fluorescence intensity analysis, and replaced with fresh buffer as stated 
in Section 4.2.8. Free DOX (31 µM) was also dialyzed under the same condition as a 
control. Each experiment was carried out with three replicates (n = 3) and the data is 
presented as mean ± standard deviation. 
 
5.2.6. Determination of the cellular Kd of aptamers 
The MCF7 and RAW cells were each divided into tubes of 2 × 105 cells. The MCF7 
and RAW cells were centrifuged down (1500 rpm, 5 min) and the cells resuspended 
in 400 µl of cell culture medium containing varying concentrations (0, 7.8, 15.6, 31.3, 
62.5, 125, 250 and 500 nM) of CY5-APT or CY5-L3. For MCF7 cells, CY5-APT-
DOX and CY5-L3-DOX (with aptamer to DOX molar ratio of 1.1, at aptamer 
concentrations of 0, 7.8, 15.6, 31.3, 62.5, 125, 250 and 500 nM) in cell culture 
medium were also prepared and mixed with the cells. The suspensions were then 
incubated for 30 min at 25oC and 30 rpm on a rotamixer (Intelli-mixer MyLab). After 
which, the cells were washed twice with 500 µl of PBS buffer and resuspended in 50 
µl of PBS buffer. The fluorescence of the aptamer-bound cells was read at excitation 
wavelength of 600 nm and emission wavelength of 668 nm using a microplate reader 





(Tecan infinite M200). Each experiment was carried out with three replicates (n = 3) 
and the data is presented as mean ± standard deviation. The relative fluorescence 
intensity of the cells (obtained after normalization of fluorescence intensity of 
aptamer-bound cells against cell inherent fluorescence) was plotted against aptamer 
concentration, and the data was fitted to a Langmuir isotherm. The cellular Kd of 
aptamers was estimated from the Langmuir equation. 
 
5.2.7. Fluorescence microscopy 
MCF7 and RAW cells were seeded in a 24-well plate at 5 × 104 cells per well (1 ml). 
The cells were incubated at 37oC with 5% CO2 for 24 h and then washed once with 
cell growth medium (1 ml). The cells were incubated with CY5-APT, CY5-L3 or 
CY5-LIB (500 nM) in cell growth medium (400 µl per well) at 37oC with 5% CO2 for 
4 h. After incubation, the cells were washed thrice with PBS buffer (1 ml), fixed in 2% 
formaldehyde in PBS buffer (1 ml) for 30 min, washed with PBS buffer (1 ml), 
stained with Hoechst 33258 (2 µg/ml in PBS buffer, 1 ml) for 10 min, washed twice 
with PBS buffer (1ml) and stored in PBS buffer (1 ml). The imaging of cells was 
carried out with a fluorescence microscope (Nikon A1R) using CY5 and DAPI filters. 
 
5.3. Results and Discussion 
5.3.1. Design of modified APT using Mfold program 
MUC1 extracellular protein targeting aptamer APT, selected from a SELEX process 
(Ferreira et al., 2006), was truncated from both 5’ and 3’ ends to form aptamer L (i.e. 
only the stem loop of APT was retained) (Table 5.1, Figure 5.1a). This design was 
selected as the stem loops of aptamers were shown to be often involved in the binding 
to their targets (Zhou et al., 2011b). In addition, to improve the targeting and drug  





Table 5.1. ssDNA sequences of modifications of APT. L was truncated to contain 











5’NH2-C6 spacer- GATCCTTTGGATA GATCCTTTGGATA-3’ 
L3 
 
5’NH2-C6 spacer-GATCCTTTGGATA GATCCTTTGGATA GATCCTTTGGATA-3’ 
 
intercalation or delivery efficacy of the aptamer, two and three-repeat variations of L 
were synthesized, i.e. L2 and L3 respectively (Table 5.1, Figure 5.1a). The aptamers L, 
L2 and L3 were designed using the Mfold program (Zuker, 2003) to have structures 
as presented in Figure 5.1a at both room and physiological temperatures (25oC and 
37oC). In the application of these structures for drug delivery, DOX will be 
intercalated within the double-stranded 5’-GC-3’ or 5’-CG-3’ sequences. APT and L 
have two cytosine-guanine (CG) bonds while L2 and L3 possess four and six CG 
bonds, respectively. Two CG bonds are expected to form the pseudo double-stranded 
DNA which will intercalate a DOX molecule. By retaining the aptamer structures at 
both room and physiological temperatures, the premature release of DOX from the 
aptamer-DOX complexes (due to aptamer structural change during transfer from the 
preparation tube to the cells) will be avoided.  
 
5.3.2. Intercalation efficacy of DOX with MUC1-targeting aptamers 
The ability of the aptamers to intercalate DOX is shown in Figure 5.1b. DOX has 
inherent fluorescence that decreases upon intercalation within the CG bond of the 
aptamer. As the number of stem loops increases, the ability of the aptamer to 
intercalate DOX increases. The aptamer to DOX molar ratio required to quench 98% 
of the original DOX fluorescence was determined to be 5.9, 3.5 and 1.1 for L, L2 and  
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L3, respectively. The intercalation of DOX by L3 is similar to that by APT. The Kd 
values of 240 nM, 1.64 µM, 470 nM and 120 nM were obtained from the Hill plots 
for APT, L, L2 and L3, respectively. In principle, an increase in DOX intercalation to 
two or three DOX molecules per aptamer for L2 or L3 could be anticipated, but this 
was not achieved. Using the Mfold program (Zuker, 2003), APT and L were found to 
possess the same predicted stem loop structure (Figure 5.1a) and free energy (dG = -
1.54 at 25oC and dG = -0.66 at 37oC). However, the DOX intercalation ability of L is 
reduced as compared to APT (Figure 5.1b). This shows that the 5’ and 3’ end 
sequences that were truncated from APT to form L may be responsible for the 
stability of DOX intercalation. DOX binding to GC bonds in DNA aptamer is 
predicted to be stabilized by both intercalation and minor groove interactions, with 
hydrogen bonding playing an important role in the sequence preference for DOX 
binding (Chaires et al., 1990). Hence, we propose that transient hydrogen bonding 
(either between the end sequences or between the end sequences and the stem loop) 
may further strengthen the hydrogen bonding of the GC bonds in APT, which in turn 
stabilizes the intercalation of DOX within the GC bonds. However, with the increase 
in the number of stem loops from L to L3, DOX intercalating ability increases due to 
the increased in presence of GC bonds from two to six. It is also possible that the 
increased non-specific hydrogen bonding between the DNA nucleotide bases of the 
aptamer L3 (accompanying the increase in number of nucleotides) further stabilizes 
the GC bonds.  
 
5.3.3. Cell cytotoxicity of DOX, APT, APT-DOX, L3 and L3-DOX 
L and L2 require an aptamer to DOX molar ratio of 5.9 and 3.5, respectively, to 
achieve complete intercalation of DOX. However, this means that some of the 





aptamers will be without DOX (e.g. for L, only one DOX molecule will be associated 
with every six aptamers). This will lower the treatment efficacy as the DOX-depleted 
aptamer (which will compete with the DOX-loaded aptamer for the same site on the 
cells) lacks cytotoxic property. On the other hand, APT and L3 require an aptamer to 
DOX molar ratio of 1.1 to achieve complete intercalation of DOX, indicating that on 
average, each aptamer will have a DOX molecule. Hence, the cell cytotoxicity test 
(MTT assay) was carried out with only APT and L3 at an aptamer to DOX molar ratio 
of 1.1. The MTT assay shows that while RAW is more sensitive to free DOX (16.1% 
cell viability for RAW compared to 38.1% for MCF7 at Day 1), APT-DOX increases 
the viability of RAW about 3-fold to 51.5% while L3-DOX increases the viability of 
RAW about 5-fold to 80.1% (Figure 5.2a). This may be due to the increase in 
selective targeting of L3 aptamer (with the presence of three targeting stem loops) to 
MCF7 over RAW cells. For MCF7 treated with DOX and aptamer-DOX complexes, 
the cytotoxicity of DOX toward the cells is slightly reduced upon intercalation by the 
aptamers APT and L3 (increase in cell viability from 38.1% with free DOX to 46% 
with APT-DOX and L3-DOX). This is probably due to the different mechanisms in 
which free DOX and L3-DOX interact with the cells. Free DOX was reported to show 
rapid cell penetration through the cell membrane (Lee et al., 2002) but without 
selective cytotoxicity to MCF7 over RAW cells. With the L3-DOX at a concentration 
of 5 µM, non-specific uptake is reduced (illustrated by the increase in cell viability of 
RAW cells). The uptake of the L3-DOX complex may be only via receptor-mediated 
endocytosis. The release of DOX from the L3-DOX complex in the cells will also 
require some time. Hence, these factors may account for the lower cytotoxicity of L3-
DOX as compared to the same concentration of free DOX. Both Day 1 (Figure 5.2a) 
and Day 3 data (Figure 5.2b) exhibits a similar trend, but the Day 3 results generally 





show slightly higher cytotoxicity due to the release of DOX from the aptamer 







Figure 5.2. MTT assay of MCF7 and RAW cells after 4 h incubation with DOX, 
aptamers (APT or L3), aptamer-DOX complexes (APT-DOX or L3-DOX), or cell 
growth medium as control, followed by another a) 1 day or b) 3 days of cell growth. * 
denotes significant increase (p < 0.05, n = 3) in cell viability as compared to the non-
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5.3.4. DOX release from APT-DOX or L3-DOX complex 
The time-dependent release of DOX from APT-DOX and L3-DOX is shown in Figure 
5.3. The significantly lower DOX release rates for both APT-DOX and L3-DOX 
(29.3% and 22.4%, respectively at 72 h) as compared to the free DOX release rate 
(94.6% at 72 h) indicate that the aptamers and DOX form affinity complexes which 
prevent the DOX molecules from diffusing through the dialysis membrane. L3 has a 
higher affinity for DOX than APT as indicated by both lower DOX release rate and 
Kd obtained from the Hill plot in Figure 5.1b for L3-DOX. This is likely due to the 




Figure 5.3. Time-dependent release of DOX from aptamer-DOX complexes (APT-





































5.3.5. Study of MUC1-targeting aptamer selective interaction with MCF7 cells 
using fluorescence microscopy 
Fluorescence microscopy images of MCF7 cells after incubation with CY5 tagged 
APT and L3 (Figure 5.4) show that the targeting efficacy of APT is higher than that of 
L3 (as indicated by the brighter fluorescence for CY5-APT treated cells). The 
increase in negative charge, molecular weight and/or conformation change of L3 as 
compared to APT may have affected its targeting efficacy. For control RAW cells, the 
targeting by both aptamers is much reduced which indicates the selectivity of CY5 
tagged APT and L3 for MCF7 cells. Control CY5-LIB also shows negligible binding 
to both MCF7 and RAW cells.  
 
5.3.6. Determination of the cellular Kd of aptamers 
To determine the cellular Kd of aptamers, different concentrations of CY5-APT, CY5-
L3, CY5-APT-DOX and CY5-L3-DOX were incubated with MCF7 and/or control 
RAW cells. After washing off excess aptamers from the cells, the fluorescence 
intensity of the CY5-aptamer and CY5-aptamer-DOX stained cells was plotted 
against the aptamer concentrations, and Kd values of the aptamers for the MCF7 and 
RAW cells were determined using the Langmuir isotherm (Figure 5.5). For the MCF7 
cells, the Kd for APT and L3 were 3.84 nM and 173.81 nM, respectively, with R2 
values of 0.98 and 0.93. In most previous investigations, this test was conducted at 
4oC for around 30 min to minimize cell endocytosis. However, in our case, the 
aptamer structures for both APT and L3 are altered at 4oC (Figure 5.6); hence the 
determination of the Kd was performed at room temperature for 30 min. In this assay, 
it was found that the interactions of L3 with MCF7 cells were much reduced when 
lower concentrations of L3 (7.8 - 250 nM) were used compared to the interaction of 










Figure 5.4. Fluorescence microscopy images of a) MCF7 and b) RAW cells after 4 h 
incubation with CY5-APT, CY5-L3 or CY5-LIB. The cell nuclei were stained with 
Hoechst. 
 







Figure 5.5. Binding of CY5-APT, CY5-L3 aptamers or their DOX complexes to 
MCF7 and RAW cells at various aptamer concentrations. The data was fitted to a 
Langmuir isotherm (solid lines for CY5-APT and CY5-L3; dashed lines for CY5-
APT-DOX and CY5-L3-DOX) and their aptamer cellular Kd was estimated using 




Figure 5.6. Two-dimensional secondary structures of MUC1-targeting aptamers 
(APT and L3) at 4oC and 37oC predicted using Mfold program (Zuker, 2003).  
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APT with MCF7 cells at the same concentrations. However, as the aptamer 
concentration increased to 500 nM, the amount of CY5-L3 bound to the cells 
increased to approximately 90% that of CY5-APT as indicated by the fluorescence 
intensity of cells exhibited by the CY5-L3 and CY5-APT stained MCF7 cells.  
 
With the intercalation of DOX molecules (Figure 5.5), the Kd of CY5-APT-DOX and 
CY5-L3-DOX for MCF7 cells increases to 5.67 nM and 276.44 nM, respectively, 
with R2 values of 0.97 and 0.96. This indicates that the intercalation of DOX within 
the aptamers APT and L3 decreases the affinity of the aptamers for MCF7 cells 
slightly, possibly due to the change in conformation of aptamers upon DOX 
intercalation. The amount of APT bound to MCF7 cells at 500 nM aptamer 
concentration decreases by 10% once DOX is intercalated in APT, while the amount 
of L3 bound at the same aptamer concentration remains similar with or without DOX.  
 
On the other hand, the fluorescence intensity for CY5-L3 stained RAW cells was 
reduced by approximately 2-fold as compared to CY5-APT stained RAW cells 
(Figure 5.5). This may account for the reduced cytotoxicity of L3-DOX toward RAW 
as compared to that of APT-DOX (Figure 5.2). The differences in molecular weight 
of the aptamer (39 mer for L3 vs. 25 mer for APT) and aptamer structure may have 












The designer tridentate ssDNA aptamer (L3) enables the specific delivery of DOX to 
the MUC1 protein overexpressing cancer cell line (MCF7) while avoiding the 
macrophage cells. This method does not require chemical modification of the aptamer, 
optimization and subsequent purification, thus saving time and cost. However, for the 
purpose of pure immunostaining of MUC1 protein on cells (i.e. when it is 
unnecessary to consider macrophage evasion by aptamers), APT would be preferred 
over L3. Since APT exhibits a stronger affinity for the MUC1 protein, such staining 
could be completed in a shorter time. This study illustrates that the specificity and 
affinity of the MUC1 aptamers to the extracellular MUC1 receptors could be easily 




















STUDY OF THE AFFINITY LIGANDS FOR USE IN 
TARGETED BLADDER CANCER THERAPY 
  
6.1. Introduction  
The current treatment methods and limitations of bladder cancer were reviewed in 
Section 2.8. Intravesical therapy is preferred over systemic chemotherapy for maximal 
delivery of therapeutic drugs to the cancer site while minimizing systemic side effects 
(GuhaSarkar and Banerjee, 2010). However, even with intravesical therapy, some 
possible reasons for the high cancer recurrence rate include 1) the removal of 
therapeutic drugs with each voiding of urine and thus the difficulty in maintaining the 
effective therapeutic dose, 2) the heterogeneity of the bladder cancer cells (transitional 
cell carcinoma, squamous cell carcinoma and adenocarcinoma) renders the 
determination of appropriate treatment a challenge, and 3) the lack of high affinity 
targeting ligands that can be used for drug delivery to bladder cancer cells 
(GuhaSarkar and Banerjee, 2010).  
 
Targeted bladder cancer therapy is essential to allow better life quality to the patient 
during treatment and a more rapid recovery. The retention of bladder cancer 
therapeutic drugs at the cancer site, even with urine voiding, will allow longer drug 
therapeutic time and higher efficacy of treatment. This might also reduce the high 
recurrence rate currently encountered. 
 





Thus far, bladder cancer cell lines are not well characterized, with the cell surface 
overexpressed protein being relatively unknown. Some reported protein receptors 
present on bladder cancer cells are MUC1, EGFR, HER2, VEGF, platelet derived 
growth factor receptor β, and fibroblast growth factor receptor 3 (Bellmunt et al., 
2003; Black et al., 2007; Hughes et al., 2000). However, most of the research 
performed until now is based on clinical bladder cancer cell specimens that are not 
widely available for comprehensive drug delivery study. There is no consensus on a 
group of widely used ligands that can be used in targeting the bladder cancer cells 
(Fritsche et al., 2006).  
 
In Chapters 4 and 5, MUC1 targeting aptamer (S1.3 or APT) was investigated for its 
affinity for MUC1 overexpressing breast cancer cell line, MCF7. In this chapter, APT 
was tested for its affinity for MUC1 overexpressing bladder cancer cell line, MGH-
U3 (Bergeron et al., 1996). This is because 1) we would like to study if APT can 
recognize MUC1 present on different cancer cell lines, and 2) there is no known 
aptamer that can be used for targeted bladder cancer drug delivery. In addition, 
several other reported ligands (MUC1 antibody, EGFR targeting RNA aptamer, 
HER2 targeting RNA aptamer and ανβ3 integrin targeting PLZ4 peptide aptamer) 
(Esposito et al., 2011b; Kim and Jeong, 2011; Zhang et al., 2012) against bladder 
cancer cell lines (T24, UM-UC-3 and MGH-U3) were investigated to determine their 
suitability as targeting ligands for use in bladder cancer therapy. T24 and UM-UC-3 









6.2. Experimental Section 
6.2.1. Materials 
MUC1 antibody (MAB6298) and donkey anti-mouse IgG NL557 (NL007) were from 
R&D Systems, USA. CY3-labeled EGFR targeting RNA aptamer (CY3-CL4: 5’CY3-
GCCUUAGUAACGUGCUUUGAUGUCGAUUCGACAGGAGGC-3’), its 
scrambled sequence as control (CY3-CL4sc: 5’CY3-
UUCGUACCGGGUAGGUUGG CUUGCACAUAGAACGUGUCA-3’) (Esposito et 
al., 2011b), and CY3-labeled HER2 targeting RNA aptamer (CY3-mini RNA: 5’CY3-
AGCCGCGAGGGGAGGGAUAGGGUAGGGCGCGGCU-3’) (Kim and Jeong, 
2011) were synthesized by IDT, Singapore. Cyclic peptide biotin-PLZ4 (biotin-
CQDGRMGFC with disulfide bond between CYS1 and CYS9) (Zhang et al., 2012) 
was synthesized by GL Biochem, Shanghai. CY3-streptavidin (S6402) was purchased 
from Sigma-Aldrich, Singapore.  
 
6.2.2. Cell culture 
T24 (HTB-4) and UM-UC-3 (CRL-1749) bladder cancer cells (ATCC) were cultured 
in McCoy 5A and high glucose DMEM cell culture medium, respectively. MGH-U3 
bladder cancer cells (a gift from Dr. Y. Fradet, Laval University Cancer Research 
Center) were cultured in minimum essential medium (MEM) alpha cell culture 
medium. SV-HUC-1 (CRL-9520, ATCC) immortalized normal bladder cells were 
cultured in F-12K cell culture medium. MCF7 and SK-BR-3 (HTB-30, ATCC) breast 
cancer cells were cultured in high glucose DMEM cell culture medium. All media 
were supplemented with 10% fetal bovine serum and 100 U/ml penicillin-
streptomycin. The cell cultures were maintained at 37oC under a humidified 
atmosphere of 5% CO2.  





6.2.3. Fluorescence microscopy 
T24, UM-UC-3, MGH-U3, SV-HUC-1, MCF7 and SK-BR-3 cells were seeded in 24-
well plates at 5 × 104 cells per well (1 ml). The cells were incubated at 37oC with 5% 
CO2 for 24 h and then washed once with their respective cell growth medium (1 ml).  
 
MGH-U3 cells were incubated with CY5-APT or control CY5-LIB (500 nM) in cell 
growth medium (400 µl per well) at 37oC with 5% CO2 for 1 or 4 h (Note: Sequence 
details for CY5-APT and CY5-LIB are available in Chapter 3). Subsequently, the cell 
staining and imaging were carried out using the procedures stated in Section 5.2.7. 
Under similar experimental conditions, T24, UM-UC-3 and MGH-U3 cells were 
incubated with EGFR RNA aptamer (CY3-CL4) and its control scrambled aptamer 
(CY3-CL4sc). In addition, T24, UM-UC-3, MGH-U3, SV-HUC-1, SK-BR-3 and 
MCF7 cells were incubated with HER2 RNA aptamer (CY3-mini RNA) for 1 h.  
 
MGH-U3 and MCF7 cells were incubated with primary MUC1 antibody (10 µg/ml) 
in cell growth medium (400 µl per well) at 37oC with 5% CO2 for 1 or 4 h. After 
incubation, the cells were washed thrice with PBS buffer (1 ml), fixed in 2% 
formaldehyde in PBS buffer (1 ml) for 30 min, washed with PBS buffer (1 ml), 
stained with secondary mouse IgG antibody (5 µg/ml in PBS buffer, 400 µl) for 1 h, 
washed twice with PBS buffer (1 ml), stained with Hoechst 33258 (2 µg/ml in PBS 
buffer, 1 ml) for 10 min, washed twice with PBS buffer (1ml) and stored in PBS 
buffer (1 ml). The imaging of cells was carried out with a fluorescence microscope 
(Nikon A1R) using TRITC and DAPI filters. 
 





T24 cells were incubated with biotin-PLZ4 (1 µM) in cell growth medium (400 µl per 
well) at 37oC with 5% CO2 for 1 or 4 h. After incubation, the cells were washed thrice 
with PBS buffer (1 ml), fixed in 2% formaldehyde in PBS buffer (1 ml) for 30 min, 
washed with PBS buffer (1 ml), stained with CY3-streptavidin (0.5 µg/ml in PBS 
buffer, 400 µl) for 15 min, washed twice with PBS buffer (1 ml) and stored in PBS 
buffer (1 ml). The imaging of cells was carried out with a fluorescence microscope 
(Nikon A1R) using TRITC filter. 
 
6.3. Results and Discussion 
A summary of the potential bladder cancer targeting ligands investigated in Chapter 6 
is presented in Table 6.1. These ligands target either MUC1, EGFR, HER2 or ανβ3 
integrin cell surface protein which is often overexpressed in many cancer cells 
(Esposito et al., 2011b; Ferreira et al., 2006; Kim and Jeong, 2011; Zhang et al., 2012). 
 
Table 6.1. Ligands, their known protein receptors, and the bladder cancer cell lines 
investigated in Chapter 6. 
 
Ligand Protein receptor  Cell line 
MUC1 targeting ssDNA 
aptamer, S1.3 or APT  
(Ferreira et al., 2006) 
 
MUC1 MGH-U3 
MUC1 antibody  
(MAB6298, R&D Systems) 
 
MUC1 MGH-U3 
EGFR targeting RNA aptamer, 
CL4  
(Esposito et al., 2011b)  
 
EGFR T24, UM-UC-3, MGH-U3 
HER2 targeting RNA aptamer, 
mini RNA 
(Kim and Jeong, 2011) 
 
HER2 T24, UM-UC-3, MGH-U3 
Bladder cancer cell targeting 
peptide aptamer, PLZ4 
(Zhang et al., 2012)  
ανβ3 integrin T24 
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Figure 6.2. MGH-U3 bladder cancer cells after a) 1 h and b) 4 h incubation at 37oC 
and 5% CO2 with either CY5-APT or control CY5-LIB. The cell nuclei were stained 













and exists as variable tandem repeats (Bergeron et al., 1996). The different MUC1 
protein isoforms encoded by mRNA of different lengths could be presented in varied 
glycoforms and tandem repeats. Hence, this affects the interaction of CY5-APT with 
the MUC1 protein on MGH-U3. 
 
In addition, it was reported that murine MUC1 antibody HMFG-2 raised against 
delipidated human milk fat globule and milk epithelial cells (Taylor-Papadimitriou et 
al., 1981) [targeting DTR of the MUC1 peptide sequence, (Taylor-Papadimitriou et al., 
1993)] did not show affinity for MGH-U3 (Bergeron et al., 1996). However, murine 
MUC1 antibody DF3 raised against membrane enriched fraction of a human breast 
carcinoma (Abe and Kufe, 1989) [targeting TRPAPGS of the MUC1 peptide 
sequence, (Perey et al., 1992)] showed affinity for MGH-U3 (Bergeron et al., 1996). 
Both antibody-antigen interaction studies were performed using Western blot analysis. 
This shows that the availability of the MUC1 protein specific amino acid sequence on 
the cell surface is not the only prerequisite for antibody-antigen interaction. The 
varying degree of glycosylation and number of tandem repeats of MUC1 protein in 
different cellular system will also affect the interaction of ligand (either aptamer or 
antibody) with protein antigen. 
 
6.3.2. Affinity analysis of MUC1 antibody against MGH-U3 and MCF7 
A commercially purchased murine MUC1 antibody (MAB6298) raised against E. 
coli-derived recombinant human MUC1 (PAPGSTAPPAHGVTSAPDTR) was tested 
for its interaction with MGH-U3 cells, as well as with MCF7 cells as control. After 
incubation of primary MUC1 antibody with MGH-U3 and MCF7 for 1 h, no 
significant antibody-cell interaction was detected for both cell lines (Figure 6.3). 





Further incubation of the primary MUC1 antibody with the cells for up to 4 h [in cell 
growth medium with (Figure 6.4) or without fetal bovine serum (Figure 6.5)] resulted 
in no significant binding of MUC1 antibody with either MGH-U3 or MCF7. In 
addition, since secondary antibody staining was initially performed after 2% 
formaldehyde fixation, there is a possibility that the primary antibody might not be 
recognized by the secondary antibody. Hence, the experiment was repeated with 
secondary antibody staining performed first before fixation (all the other procedures 
remained the same). However, this did not increase the fluorescence signal detected 
either (Figure 6.6).  
 
The cells in Figure 6.6 appear more rounded (as compared to cells in Figures 6.3, 6.4 
and 6.5) as the cells were first incubated with secondary mouse IgG antibody in PBS 
buffer for 1 h before cell fixation. The cells tend to become less adhesive to the 
culture well surface when incubated in buffer instead of cell culture medium. In 
Figures 6.3, 6.4 and 6.5, the cells were fixed before incubation with secondary mouse 
IgG antibody in PBS buffer and thus their cell morphologies were maintained. 
However, these changes in cell morphologies are not expected to be the factor 
limiting the MUC1 receptor-targeting ligand interaction. Both APT and L3 aptamers 
were shown to target MCF7 cells regardless of whether the cells were in an adherent 
(Figure 5.4a) or a suspended state (Figure 5.5).  
 
Antibody ligands that can identify their antigens in immunohistochemistry or Western 
blotting (such as MAB6298) may not work in drug delivery to live cells. First, the 
antigen conformation after fixation in immunohistochemistry or denaturation in 
Western blotting can be different from its native state. Second, the reaction conditions 





(buffer, temperature and time duration) used for immunohistochemistry and Western 
blotting are different from those of drug delivery conditions. These may render the 
antibody unable to recognize the antigen. The MUC1 antibody (MAB6298) is not 
explored further since it does not target the MUC1 overexpressing cells under cell 


















































Figure 6.3. a) MGH-U3 bladder cancer cells after 1 h incubation at 37oC and 5% CO2 
with primary MUC1 antibody, followed by staining with secondary mouse IgG 
antibody. For control, MGH-U3 bladder cancer cells were incubated with cell culture 
medium instead, followed by staining with secondary antibody. The cell nuclei were 
stained with Hoechst. The microscopy images were obtained using bright field, 
TRITC and DAPI filters, and b) MCF7 breast cancer cells were used instead of 
















Figure 6.4. a) MGH-U3 bladder cancer cells after 4 h incubation at 37oC and 5% CO2 
with primary MUC1 antibody, followed by staining with secondary mouse IgG 
antibody. For control, MGH-U3 bladder cancer cells were incubated with cell culture 
medium instead, followed by staining with secondary antibody. The cell nuclei were 
stained with Hoechst. The microscopy images were obtained using bright field, 
TRITC and DAPI filters, and b) MCF7 breast cancer cells were used instead of 



















Figure 6.5. a) MGH-U3 bladder cancer cells after 4 h incubation at 37oC and 5% CO2 
with primary MUC1 antibody in cell culture medium (without fetal bovine serum), 
followed by staining with secondary mouse IgG antibody. For control, MGH-U3 
bladder cancer cells were incubated with cell culture medium (without fetal bovine 
serum) instead, followed by staining with secondary antibody. The cell nuclei were 
stained with Hoechst. The microscopy images were obtained using bright field, 
TRITC and DAPI filters, and b) MCF7 breast cancer cells were used instead of 


















Figure 6.6. a) MGH-U3 bladder cancer cells after 4 h incubation at 37oC and 5% CO2 
with primary MUC1 antibody in cell culture medium (without fetal bovine serum), 
followed by staining with secondary mouse IgG antibody prior to cell fixation. For 
control, MGH-U3 bladder cancer cells were incubated with cell culture medium 
(without fetal bovine serum) instead, followed by staining with secondary antibody 
prior to cell fixation. The cell nuclei were stained with Hoechst. The microscopy 
images were obtained using bright field, TRITC and DAPI filters, and b) MCF7 










6.3.3. Affinity analysis of EGFR RNA aptamer (CY3-CL4) against T24, UM-UC-
3 and MGH-U3 
EGFR overexpression promotes tumor angiogenesis and metastasis, and is associated 
with poor prognosis in various human malignancies including glioma, lung, breast 
and bladder cancers (Bellmunt et al., 2003; Esposito et al., 2011b; Hynes and Lane, 
2005; Yarden and Sliwkowski, 2001). However, no aptamer has been reported to 
target EGFR receptor on the bladder cancer cells. CL4 (a RNA aptamer selected via 
cell SELEX to target A549 lung cancer cell line overexpressing EGFR) was shown to 
inhibit A549 cell proliferation in vitro and limit growth of A549-mouse xenografts in 
vivo (Esposito et al., 2011b). Hence, we first investigated the interaction of CY3-CL4 
RNA aptamer with three bladder cancer cell lines (T24, UM-UC-3 and MGH-U3) 
expressing different amounts of EGFR (Havaleshko et al., 2009). CY3-CL4sc, the 
scrambled sequence of CY3-CL4, was used as the control RNA aptamer. After 1 h 
incubation of CY3-CL4 and CY3-CL4sc aptamers with the cell lines, no increase in 
fluorescence signal was observed for cells incubated with CY3-CL4 as compared to 
those incubated with CY3-CL4sc (Figure 6.7). When the incubation time of aptamers 
with the three cell lines was increased to 4 h, both aptamers exhibited increased 
interaction with the three cell lines (compared to the 1 h incubation of the aptamers 
with the respective cell lines) (Figure 6.8). However, for all three cell lines, no 
significant interaction with CY3-CL4 was observed as compared to CY3-CL4sc 
(Figure 6.8). This indicates that CY3-CL4 does not show specific interaction to all 
three cell lines investigated, probably due to insufficient expression or differential 
isoform of EGFR (Gan et al., 2012) on T24, UM-UC-3 and MGH-U3 bladder cancer 
cells as compared to A549 lung cancer cells. The various isoforms of EGFR are also 





known to be recognized differently by anti-EGFR small molecular drugs (e.g. 



























































Figure 6.7. a) T24, b) UM-UC-3 and c) MGH-U3 bladder cancer cells after 1 h 
incubation at 37oC and 5% CO2 with either CY3-CL4 or CY3-CL4sc. The cell nuclei 
were stained with Hoechst. The microscopy images were obtained using bright field, 
TRITC and DAPI filters.  
 












Figure 6.8. a) T24, b) UM-UC-3 and c) MGH-U3 bladder cancer cells after 4 h 
incubation at 37oC and 5% CO2 with either CY3-CL4 or CY3-CL4sc. The cell nuclei 
were stained with Hoechst. The microscopy images were obtained using bright field, 
TRITC and DAPI filters.  
 





6.3.4. Affinity analysis of HER2 RNA aptamer (CY3-mini RNA) against T24, 
UM-UC-3 and MGH-U3 
HER2 protein is overexpressed in various carcinomas including breast and bladder 
cancers, and this expression is related to poor disease prognosis (Havaleshko et al., 
2009; Rusnak et al., 2007). A HER2 targeting RNA aptamer (mini RNA) was recently 
identified via in vitro SELEX using recombinant glutathione S-transferase (GST)-
tagged HER2 protein (22-122 amino acids) (Abnova, Taipei, Taiwan) as the target 
(Kim and Jeong, 2011). Although mini RNA was shown to target HER2 positive 
breast cancer cell lines (KPL-4 and MDA-MB-453) (Kim and Jeong, 2011), it was not 
known if the aptamer could target T24, UM-UC-3 or MGH-U3 bladder cancer cell 
line expressing different amounts of HER2 (Table 6.2). Herein, we investigated the 
interaction of CY3-mini RNA with the three bladder cancer cell lines (T24, UM-UC-3 
and MGH-U3), with CY3-CL4sc as control RNA. After 1 h incubation of CY3-mini 
RNA and CY3-CL4sc aptamers with the three cell lines, increase in fluorescence 
signal was observed for all cell lines incubated with CY3-mini RNA, as compared 
with the respective cell lines incubated with CY3-CL4sc (Figure 6.9). This indicates 
that CY3-mini RNA preferentially interacts with all three bladder cancer cell lines as 


















Table 6.2. HER2 expression on various bladder and breast cancer cell lines (relative 
to HER2 expression on MCF7 breast cancer cell line) (Havaleshko et al., 2009; 
Kurebayashi et al., 1999; Rusnak et al., 2007). 
 
Cell line Relative HER2 expression 


































Figure 6.9. a) T24, b) UM-UC-3 and c) MGH-U3 bladder cancer cells after 1 h 
incubation at 37oC and 5% CO2 with either CY3-mini RNA or CY3-CL4sc. The cell 
nuclei were stained with Hoechst. The microscopy images were obtained using bright 
field, TRITC and DAPI filters. 
 





However, CY3-mini RNA interaction with SV-HUC-1 (immortalized normal bladder 
cells) exceeded the aptamer interaction with all the other three bladder cancer cell 
lines (Figure 6.10a). The TRITC fluorescence intensity for CY3-mini RNA stained 
T24, UM-UC-3 and MGH-U3 in Figure 6.10a appears weaker compared to their 
corresponding images in Figures 6.9 or 6.10b. This is because of the shorter exposure 
time used for the images in Figure 6.10a to avoid oversaturation of the CY3-mini 
RNA stained SV-HUC-1 images. The strong affinity of CY3-mini RNA to SV-HUC-
1 was unexpected since HER2 overexpression is known to occur in cancer cells but 
not normal bladder cells. It was thus suspected that other proteins present on the SV-
HUC-1 cell surface might have strong interaction with the CY3-mini RNA.  
 
As normal bladder cells have limited passage number, HUC-1 (normal human 
uroepithelium cells) was transformed with simian virus 40 (SV40) to enable the cell 
immortalization (Christian et al., 1987). SV-HUC-1 cells thus obtained were shown to 
possess the ability to remain in continuous culture for more than 2 years while 
remaining non-tumorigenic (Christian et al., 1987). The SV40 transformed cells were 
also reported to express new SV40-induced antigens: large T antigen (tumor antigen, 
MW 94 kDa) in the cell nucleus, large T antigen related cell surface antigen, and 
small t antigen (MW 17 kDa) in the cytoplasm (Basilico, 1984). The large T antigen 
contains DNA and RNA binding domains (Khandjian et al., 1982; Luo et al., 1996; 
Wessel et al., 1992). Although large T antigens are known to interact with specific 
DNA sequence GAGGC, they were also shown to interact to a lesser extent with non-
specific DNA sequences (Wessel et al., 1992). In the CY3-mini RNA used in our 
study, there are two repeats of GAGG which is a majority part of the GAGGC 
sequence (i.e. 5’CY3-AGCCGCGAGGGGAGGGAUAGGGUAGGGCGCGGCU-3’). 





In light of these, it could be possible that the large T antigen related cell surface 
antigen possesses RNA binding domains and thus resulting in its high interaction with 
CY3-mini RNA. Hence, SV-HUC-1 should not be used as a control cell line for study 
of bladder cancer targeted drug delivery when nucleic acids are used as part of the 



















Figure 6.10. a) Bladder cancer cells (T24, UM-UC-3 and MGH-U3) and control 
immortalized normal bladder cells (SV-HUC-1) after 1 h incubation at 37oC and 5% 
CO2 with CY3-mini RNA. The cell nuclei were stained with Hoechst. The 
microscopy images were obtained using bright field, TRITC and DAPI filters, and b) 
Bladder cancer cells (T24, UM-UC-3 and MGH-U3), HER2 overexpressing breast 
cancer cells (SK-BR-3) as positive control and low HER2 expressing breast cancer 
cells (MCF7) as negative control were incubated for 1 h with CY3-mini RNA. Cell 
staining and imaging procedures were as described in a).  
 





In addition, when compared to the interaction of CY3-mini RNA with SK-BR-3 
(HER2 overexpressing breast cancer cells as positive control) and MCF7 (low HER2 
expressing breast cancer cells as negative control) (Rusnak et al., 2007), MCF7 
showed similar degree of fluorescence intensity as UM-UC-3 (Figure 6.10b). T24 and 
MGH-U3 showed similar degree of reduced interaction (as compared to MCF7 and 
UM-UC-3), and SK-BR-3 showed the least interaction among all the investigated cell 
lines (Figure 6.10b). These results were against our initial expectations; since SK-BR-
3 overexpresses HER2 (Table 6.2), it was expected to have the highest fluorescence 
intensity; since MCF7 has low HER2 expression, it was expected to have the lowest 
fluorescence intensity.  
 
In the work by Kim and Jeong (2011), the mini RNA was incubated with the cells at 
room temperature. The mini RNA structures as predicted by Mfold program (Zuker, 
2003) at both 25oC and 37oC are the same. Hence, structural change (due to difference 
in experimental temperature) is not expected to affect the affinity between mini RNA 
and the cells. Another factor to consider is the amount of HER2 expressed on the 
various cell lines. MCF7 and UM-UC-3 cell lines displayed the highest fluorescence 
intensity (Figure 6.10b) despite having the least HER2 expression (Table 6.2). The 
increase in HER2 expression for T24 and MGH-U3 (Table 6.2) did not lead to 
increase in fluorescence intensity (Figure 6.10b). Furthermore, one of the cell lines 
with the highest HER2 expression (SK-BR-3) (Table 6.2) exhibited weak interaction 
with CY3-mini RNA (Figure 6.10b). Since it was reported by Kim and Jeong (2011) 
that mini RNA showed preferential interaction with HER2 overexpressing KPL-4 and 
MDA-MB-453 cell lines, this indicates that the presence of HER2 alone is insufficient 
to ensure interaction with the mini RNA.  





Both KPL-4 and SK-BR-3 cell lines express EGFR, HER2, human epidermal growth 
factor receptor 3 (HER3) and human epidermal growth factor receptor 4 (HER4) 
proteins on the cell surfaces (Kurebayashi et al., 1999). EGFR, HER3 and HER4 are 
proteins often present in parallel with HER2 protein. Among the four protein 
receptors, HER2, HER3 and HER4 expressions are not expected to be the factors to 
limit mini RNA interaction with SK-BR-3. This is because the total HER2 expression 
on SK-BR-3 is similar to that of KPL-4 (Table 6.2), while HER3 and HER4 
expression is higher in SK-BR-3 as compared to KPL-4 (Kurebayashi et al., 1999). 
Although the expression level of EGFR in SK-BR-3 is lower than that in KPL-4 
(Kurebayashi et al., 1999), it was verified by Kim and Jeong (2011) that EGFR 
overexpressing cell line A431 showed no fluorescence intensity after incubation with 
mini RNA (indicating low affinity of mini RNA for EGFR).  
 
Considering all of the above, it seems that HER2 structure itself is preventing the 
interaction of mini RNA with SK-BR-3 cells. HER2, a 185 kDa protein in full length, 
is known to exist in different truncated forms (Sasso et al., 2011). Mini RNA showed 
stronger interaction with KPL-4 than with MDA-MB-453 cells (Kim and Jeong, 
2011). Although KPL-4 has a higher HER2 expression level than MDA-MB-453 
(Table 6.2), KPL-4 has most of its HER2 being expressed as the 95 kDa truncated 
protein (~ 73%) and only about 27% as the 185 kDa full length protein (Damiano et 
al., 2009), while MDA-MB-453 has most of the HER2 (~ 100%) being expressed as 
the 185 kDa full length protein (Gong et al., 2010; Simeone et al., 2003). SK-BR-3, 
similar to MDA-MB-453, expresses HER2 as the 185 kDa full length protein (Gong 
et al., 2010). The mini RNA was selected using HER2 amino acids 22-122 as target 
(Kim and Jeong, 2011). The 95 kDa HER2 protein on KPL-4 cells has the first 530 





amino acids of full length HER2 protein truncated (Scaltriti et al., 2007), and thus 
does not contain the site targeted by mini RNA. The remaining amount of 185 kDa 
HER2 in KPL-4 is similar to that present in MDA-MB-453 but the targeting efficacy 
for 185 kDa HER2 in KPL-4 exceeds that in MDA-MB-453; the amount of 185 kDa 
HER2 in SK-BR-3 is nearly four times that in either KPL-4 or MDA-MB-453, but the 
targeting efficacy for 185 kDa HER2 in SK-BR-3 is low.  
 
In an attempt to understand the current observations, we reviewed how another 
targeting ligand [herceptin, an HER2 antibody (Carter et al., 1992)] interaction with 
HER2 extracellular domain might be prevented or hindered. Herceptin can recognize 
full length 185 kDa HER2 but not the truncated 95 kDa HER2 (Pohlmann et al., 
2009). However, the presence of 185 kDa HER2 does not warrant its interaction with 
herceptin as the epitopes on 185 kDa HER2 could also be sterically hindered by other 
cell surface complexes (e.g. mucin 4 protein or CD44-polymeric hyaluronan complex) 
(Pohlmann et al., 2009). Among KPL-4, MDA-MB-453 and SK-BR-3 cell lines, SK-
BR-3 is highly sensitive to herceptin, followed by MDA-MB-453 which is moderately 
sensitive to herceptin, and KPL-4 which is not sensitive to herceptin (Ichikawa et al., 
2012; Junttila et al., 2009). Since SK-BR-3 can be well recognized by herceptin, the 
epitopes on 185 kDa HER2 are present and not masked by other cell surface 
complexes. Moreover, if the herceptin antibody with molecular weight of 150 kDa 
(Carter et al., 1992) can access the epitopes, it is unlikely that the mini RNA aptamer 
with a much smaller molecular weight of 12 kDa will be hindered by the cell surface 
complexes. Instead, the structure of the full length 185 kDa HER2 could be 
differently expressed on each cell line, and thus affecting the recognition of HER2 by 
mini RNA. Hence, more investigations on mini RNA interaction with the 185 kDa 





HER2 on various cell lines and checks for aptamer cross-interaction with various 
truncated forms of HER2 should be carried out before using this aptamer for detection 
and/or therapeutic purposes to avoid false positive or negative diagnosis and 
unintended drug delivery.  
 
6.3.5. Affinity analysis of ανβ3 integrin peptide aptamer (PLZ4) against T24  
PLZ4 was selected by Zhang et al. (2012) via two rounds of suspended cell SELEX 
using OBOC combinatorial peptide library technology. In their SELEX work, 
millions of beads (each with a unique peptide sequence) were used with each bead 
contained up to 1013 copies of identical ligands. Briefly, the T24 cells were 
trypsinized, washed, resuspended and incubated with OBOC beads at cell culture 
condition. After two rounds of selection, PLZ4 was identified. Although PLZ4 was 
reported to be able to interact with T24 bladder cancer cells via ανβ3 integrin receptor, 
the interaction study was conducted either for suspended cells with PLZ4 
immobilized on the bead at 37oC in cell culture medium or adherent cells with CY5.5-
PLZ4 at 4oC in PBS buffer (Zhang et al., 2012). 
 
Under our experimental conditions, PLZ4 was incubated with adherent T24 cells in 
cell culture medium (at 37oC, 5% CO2). This is to mimic the drug delivery condition 
(i.e. adherent cells at physiological temperature, ionic strength, and in the presence of 
serum protein interference) if PLZ4 were to be used as a ligand for targeted delivery 
of therapeutic drugs to the bladder cancer cells. The fluorescence microscopy images 
shown in Figure 6.11 illustrated that there was no significant interaction between T24 
cells and PLZ4 peptide. This could be due to 1) the different conformation of the 
surface protein of T24 cells in the suspended state compared with that in the adherent 





state (i.e. the screening was performed with suspended cells, but the targeting of PLZ4 
to T24 was performed with adherent cells), 2) the temperature of 4oC vs. 37oC affects 
the conformation of the cell protein or peptide and thus affects the cell protein-peptide 
interaction, and 3) the presence of serum protein affects the cell protein-peptide 
interaction. Hence, it would be better to perform the cell SELEX under conditions 
similar to those encountered during the usage of ligands to prevent reduction or loss 















































Figure 6.11. T24 bladder cancer cells after a) 1 h and b) 4 h incubation at 37oC and 5% 
CO2 with biotinylated-PLZ4 peptide, followed by staining with CY3-streptavidin. For 
the control, T24 bladder cancer cells were incubated with McCoy 5A cell culture 
medium only, followed by staining with CY3-streptavidin. The microscopy images 
were obtained using bright field and TRITC filters.  
 






The various ligands, their protein receptors, and the bladder cancer cell lines 
investigated in Chapter 6 were presented in Table 6.1. Our results show that MUC1 
targeting ssDNA aptamer (APT), MUC1 antibody, EGFR targeting RNA aptamer 
(CL4), HER2 targeting RNA aptamer (mini RNA) and ανβ3 integrin targeting peptide 
aptamer (PLZ4) cannot specifically recognize the various bladder cancer cells (T24, 
UM-UC-3 and/or MGH-U3). APT can recognize MUC1 receptor on MCF7 (as 
discussed in Chapters 4 and 5) but not MGH-U3 cells; mini RNA can recognize 
HER2 receptor on MDA-MB-453 and KPL-4 (Kim and Jeong, 2011) but not SK-BR-
3 cells. These results indicate that the specificity of aptamers for protein receptors 
may also pose a disadvantage, as slight changes in conformation of the same receptor 
render it unrecognizable by the aptamer. In addition, the receptor-ligand interaction is 
also affected by the incubation buffer, temperature and time duration. To enable 
targeted bladder cancer therapy to be feasible, targeting ligands for the receptors that 
are overexpressed on bladder cancer cells need to be further developed. In the 
selection of targeting ligands, it will be preferable that the overexpressed receptors are 
in their native states (i.e. in the conformations that are encountered under actual 
therapy conditions). The selection buffer, temperature and receptor-ligand incubation 
duration should also be similar to the aptamer drug delivery conditions. Recently, two 
new variations of the SELEX process have been developed: cell SELEX and in vivo 
SELEX (details of these two SELEX processes were presented in Chapter 2). These 
processes attempt to present the receptors in the native form during SELEX to 
increase the chance of selecting functional aptamers for cell receptor targeting.   
 
 








7.1. Summary of Major Achievements  
Systemic chemotherapy often results in unwarranted serious side effects in patients, 
and thus adversely affecting the patients’ quality of life during treatment. Since the 
concept of targeted therapy was established around 100 years ago (Strebhardt and 
Ullrich, 2008), various drugs have been formulated with the aim to selectively kill the 
diseased cells, without affecting the functions of normal cells. This is to reduce the 
side effects via 1) reduction of non-specific drug delivery, and 2) reduction of dosage 
level made possible since specific drug delivery would ideally enable an effective 
accumulation of drug at the cancer site. Most of the targeted drugs used these days are 
antibodies that are expensive to produce, and prone to heat denaturation. Currently, 
targeting ligands that are more stable to heat, such as ssDNA and RNA aptamers, are 
being investigated. In theory, since ssDNA or RNA selection can be conducted in 
vitro, they can be selected to bind any target. This includes highly toxic target that is 
not possible with antibody, since the highly toxic target would have killed the host 
animal used for production of the antibody. With each round of the selection, 
numerous aptamer sequences would be identified and a rapid method to either check 
the bulk affinity of pool aptamer or identify high affinity aptamer would greatly 
facilitate the selection process. 
 
Hence, a fast and effective method to enable the aptamer-target analysis was first 
developed and discussed in Chapter 3. The MUC1 peptide and its targeting aptamers 





were used as models for this study. AuNPs exhibit different colors with varying 
degree of aggregation due to their LSPR properties (as discussed in Chapter 2). AuNP 
was first incubated with the ssDNA aptamers to form a layer of ssDNA ligands on the 
AuNP. In the presence of the target, the change in ssDNA aptamer conformation upon 
target interaction allowed enhanced stability of the AuNP in the ionic buffer. The 
increased stability could be quantified via the UV-vis colorimetric assay. The change 
in ssDNA aptamer conformation could also be detected using CY5 dye. ssDNA was 
first covalently linked to the CY5 dye. Upon attachment of the CY5-ssDNA aptamer 
to the AuNP, the CY5 dye was quenched due to the proximity of the CY5 dye to the 
AuNP. However, in the presence of the target peptide, the change in conformation of 
the ssDNA aptamer allowed the CY5 dye to extend further from the AuNP and the 
fluorescence was partially restored. This in combination with the increased stability of 
the AuNP in the presence of the target proved that the presence of aptamer-target 
peptide on the surface of AuNPs increased the stability of the AuNP. In addition, DLS 
and TEM results which directly show the aggregation size (the larger the aggregation, 
the lower the stability) of the AuNP also support this theory. In short, we developed a 
rapid new AuNP-based assay that could be used for the selection of ssDNA aptamers 
of high affinity from numerous sequences of the aptamers.  
 
Subsequently, the use of MUC1 aptamer in targeted cancer therapy was investigated 
and discussed in Chapters 4-6. Our focus is on breast and bladder cancer (for reasons 
mentioned in Chapter 1), some of which are known to overexpress MUC1 (i.e. MCF7 
breast cancer cell and MGH-U3 bladder cancer cell). The MUC1 aptamer (APT) 
possesses targeting ability but lacks cytotoxic property. Since APT possesses two GC 
bonds that will intercalate one DOX molecule, APT-DOX complex was prepared and 





its cytotoxicity evaluated as discussed in Chapter 4. We showed that APT intercalated 
DOX without significantly affecting either the cytotoxicity of DOX or the targeting 
efficacy of APT. However, the cell viability of control macrophages was only slightly 
better (~10%) than that of the targeted MCF7 cells. PEG was then linked to the 
aptamer to reduce the non-specific macrophage uptake of the aptamers. PEGylated 
APT-DOX complex (PEG-APT-DOX) presents significant cytotoxicity against 
MUC1 overexpressing breast cancer cells (MCF7) while minimizing adverse impact 
on the macrophages (RAW 264.7). Thus, the as-developed PEG-APT-DOX complex 
can potentially be used to combat MUC1 expressing cancers. 
 
Since the attachment of PEG to APT cannot be performed in situ during PCR, and 
requires an additional chemical functionalization step, we hypothesized that tridentate 
aptamer can be used to increase the specificity of aptamer to MCF7 cells over 
macrophages. The original MUC1 targeting aptamer reported in the literature was 
truncated to contain the active targeting region (L), and followed by synthesis of 
aptamers with two (L2) and three repeats (L3) of this active targeting region. In 
Chapter 5, the L3-DOX complex was shown to have higher specificity for MCF7 cells 
over macrophages as compared to APT-DOX. As such, L3-DOX provides a simple 
method to increase the selectivity of the aptamer without requiring chemical 
functionalization, thus saving time and cost. 
 
Although a large part of the study was conducted using MCF7 breast cancer cell line, 
we expected that the MUC1 aptamer could target other MUC1 overexpressing cell 
lines as well, since the amino acid sequence for MUC1 protein is conserved. In 
intravesical bladder cancer therapy, macrophage evasion is not critical but retaining 





the drug at cancer site during urine voiding is essential for effective treatment. Till 
now, the overexpressed proteins on bladder cancer cells, and the targeting ligands for 
the proteins are not well characterized. Hence, we investigated the affinity of various 
reported aptamers and antibody against several bladder cancer cell lines under 
physiological temperature and ionic environment. MGH-U3 is one of the cell line 
reported to overexpress MUC1 protein (Bergeron et al., 1996). However, as discussed 
in Chapter 6, MUC1 aptamer did not show interaction toward MUC1 protein 
expressed on MGH-U3. This could be due to the differences between the sequence 
repeat lengths and/or conformations of the MUC1 protein present on MCF7 breast 
cancer cells vs. MGH-U3 bladder cancer cells. The testing of a commercially 
available MUC1 antibody affinity for MGH-U3, EGFR and HER2 targeting RNA 
aptamers for T24, UM-UC-3 and MGH-U3, and ανβ3 integrin targeting peptide 
aptamer for T24 also did not yield results that indicate specificity of these aptamers 
for their respective receptors. As receptor or ligand conformation could change (and 
thus affecting their affinity for each other) under different environmental conditions 
(i.e. buffer ionic strength, temperature, incubation duration), it is important for the 
aptamer selection to be performed in conditions as close as possible to the actual 
aptamer usage environment.  
 
Overall, the research presented in this dissertation demonstrated a new methodology 
in aptamer-target affinity sorting using facile AuNP-based colorimetric assay. A 
detection limit of 8 nM MUC1 peptide was achieved in our study. In addition, we 
showed that existing aptamers can be modified through PEGylation or truncation 
followed by repeated combination of active targeting region to have 6-fold higher 
selectivity for cancer cells over macrophages. This is significant in the context of 





intravenous drug delivery where targeting agents have to avoid elimination by 
macrophages prior to reaching their targeting sites. In addition, aptamer screening 
conditions need to be determined after consideration of actual usage environment to 
increase the chance of selecting aptamers that retain affinity for their targets in actual 
therapeutics/detection purposes.  
  
7.2. Suggestions for Future Work 
Building upon the achievements described in this thesis, the following projects are 
suggested to further explore the potential of aptamer-mediated diagnosis or 
therapeutics.    
 
7.2.1. Optimization of the AuNP-based assay to increase its sensitivity and/or 
detection limit and functionality 
The sensitivity and/or detection limit of target for the AuNP-based assay could be 
enhanced via the optimization of the assay using AuNPs (or silver nanoparticles) of 
different shapes and sizes. In addition, the nanoparticles could be coated with anti-
fouling polymer (such as thiol-PEG-carboxyl), to prevent non-specific serum proteins 
from adsorbing on the nanoparticle surface, and to provide the carboxyl functional 
group for the covalent immobilization of amino-terminated aptamer on the 
nanoparticles. This will allow the investigation of aptamer-target affinity in the 
presence of serum protein for the purpose of target detection via prevention of 1) 
nanoparticle aggregation in serum of physiological ionic strength and 2) stripping of 
non-covalently immobilized aptamer from the nanoparticle surface by the serum 
proteins. This will further widen the detection capability of the assay by enabling the 





assay to be functional not only with pure peptide, but also in the direct detection of 
analyte from blood serum. 
 
7.2.2. Using aptamer-DOX complexes for in vivo drug delivery 
To study the behavior of aptamer-DOX complexes in vivo, APT, PEG-APT and L3 
could be radiolabelled prior to incubation with DOX. APT-DOX, PEG-APT-DOX 
and L3-DOX could then be intravenously injected into the mice grafted with MUC1 
breast tumors. After which, the presence of radiolabelled aptamers and released DOX 
in the blood stream, tumor and various organs could be analyzed at various time 
points. 
 
7.2.3. Using MUC1 aptamer modified PEGylated nanoparticles with Fe3O4 or 
AuNP core for 2-in-1 therapy 
DOX intercalated MUC1 targeting aptamers (APT-DOX or L3-DOX) could be 
immobilized onto biocompatible PEG nanoparticles with a magnetic Fe3O4 or AuNP 
core, for chemotherapy cum hyperthermia or chemotherapy cum photothermal 
therapy, respectively. In hyperthermia, heat is generated by the magnetic core in an 
alternating magnetic field. The generated heat could cause heat-induced cell apoptosis, 
as well as enhanced cell cytotoxicity by promoting the drug absorption. Photothermal 
therapy, on the other hand, involves the absorption of near infrared light by AuNPs 
and the subsequent conversion of the light energy to heat. Photothermal therapy is 









7.2.4. Selection of ligands for targeted bladder cancer therapy via cell SELEX 
A lack of targeting ligands for bladder cancer therapy hinders the use of targeted drug 
delivery for treatment of bladder cancer. Currently, reported studies for “targeted drug 
delivery” for bladder cancer mainly utilized mucoadhesive polymers (e.g. chitosan) or 
particles for drug delivery. These are not exactly targeted drug delivery systems, as 
drug molecules are retained in the urothelial cell wall regardless of whether the cells 
are diseased or normal. Cell SELEX could be carried out under physiological 
temperature and ionic strength to identify bladder cancer targeting aptamers that could 
be used in targeted bladder cancer therapy. With these aptamers, truly targeted drug 
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